Image result for advanced glycation end products

----------------------------------------------------------------------------------------------------------------------------------------------------------

*** SPECIAL NOTE FROM DR. WICHMAN ***

The following excellent article was reproduced from Experimental Gerontology at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359688/:

 

Exp Gerontol. Author manuscript; available in PMC 2015 Mar 14.
 
Published in final edited form as:
PMCID: PMC4359688
NIHMSID: NIHMS668279

Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness

 

1. Introduction

Age related cardiovascular disease results in part from the formation of advanced glycation end-products (AGEs). These accrue as a result of the irreversible non-enzymatic glycosylation and modification of proteins including collagen, elastin, and other functional proteins (Zieman and Kass, 2004). Cell surface receptors for AGEs, so called “RAGEs,” have been identified and coupled to pathways that initiate cellular inflammation and tissue damage. Interaction of AGE ligands with RAGE enhances receptor expression initiating a positive feedback loop (for review see Ulrich and Cerami, 2001). AGEs increase tensile stiffness and make these molecules less degradable by metalloproteinases leading to tissue accumulation. Although AGE-formation is increased in hyperglycemic conditions, it also occurs under normoglycemic conditions and is time-dependent, suggesting that it could be important in age-related vascular changes. Thus, AGEs may ultimately contribute to the ventricular and vascular stiffness seen in the aging population (Kass et al., 2001). The recent development of agents, for example Alagebrium, that can break carbon– carbon bonds and impair AGE-formation has important implications for treating age related cardiovascular dysfunction (Kass, 2003). Studies have demonstrated enhanced cardiac compliance, and cardiac output in aged dogs (Asif et al., 2000) and improved arterial compliance (Kass et al., 2001) following treatment with Alagebrium.

Reduced physical activity is well recognized to result in cardiovascular deconditioning (McGuire et al., 2001). Sedentary aging is associated with stiffening of the heart and vasculature, while life-long exercise training prevents these developments (Arbab-Zadeh et al., 2004). However, even 1 year of exercise training starting later in life (after the age of 65) does not seem to be effective at improving either arterial (Shibata and Levine, 2012) or cardiac (Fujimoto et al., 2010) stiffness in human studies. This could be due to the fact that in older individuals AGE products are already present in substantial quantities. Thus, it is possible that one mechanism by which exercise prevents stiffening of the heart and blood vessels is by limiting AGE accumulation within cardiovascular structures. The formation of AGE products is not spontaneously reversible and it is plausible that concurrent pharmacological reversal is necessary to allow full expression of the exercise response.

Ventricular–vascular coupling (VVC), or the interaction between ventricular contraction and systemic arterial vessels, is a central determinant of net cardiovascular performance (Kass, 2002). One of the seminal features of the aging vasculature is an increase in arterial stiffness or decreased arterial compliance (CA). Indices of vascular stiffness (increased pulse pressure, increased PWV) are important risk factors for cardiovascular disease, specifically in the elderly (Mitchell et al., 2010). This has led to a search for agents that increase CAand reduce pressure pulsatility such as novel AGE crosslink breakers (Kass et al., 2001). Although multiple pathways are dysregulated in aging blood vessels (Fitch et al., 2001Wang et al., 2000), including impaired endothelial vasodilator function and NO signaling, increased oxidative stress, upregulation of matrix metalloproteinases (MMP-2) (Wang and Lakatta, 2002Wang et al., 2003) and monocyte chemotactic factor and its receptor (on vascular smooth muscle cells) (Spinetti et al., 2004), AGE-accumulation may be critically important in limiting the cardiovascular response to exercise in older adults. As a corollary, AGE cross-link breakdown could enhance the response to exercise in cardiovascular structures. We therefore hypothesized that ALT, a novel AGE crosslink breaker, acts synergistically with exercise and improves the parameters of vascular and ventricular stiffness to a greater degree than either intervention alone. In this study, we determined the effect of ALT and exercise alone, or in combination, on cardiovascular parameters including parameters of vascular stiffness and diastolic and systolic functions.

2. Methods

2.1. Study design

Fifteen young (6 months) and 60 old (22–24 months) male Fisher 344 (F344) rats were obtained from the National Institute on Aging. The rats were housed three animals or less per cage, with controlled temperature and light conditions. The animals were fed and received water ad libitum. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Johns Hopkins University School of Medicine. Fisher rats at 24months develop an increase in cardiac stiffness and a decrease in contractile reserve (Pacher et al., 2004). Old rats were randomized to receive placebo, Alagebrium chloride from Alteon Corp. (ALT-711) at 1 mg/kg/day body weight by IP injection, exercise (40 min/day, 5 days/week), or a combination of ALT and exercise for 4 weeks. The young control rats remained sedentary. Control (Y) and experimental groups each consisted of 7–8 F344 rats. ALT dosage was determined from a review of previous studies, where 1 mg/kg/day was safely administered to rats, monkeys, and dogs to yield significant restorative effects of ALT on cardiovascular and diabetic pathophysiology (Liu et al., 2003Susic et al., 2004Vaitkevicius et al., 2001;Wolffenbuttel et al., 1998)

2.2. Exercise regimen

Rats were exercised daily on a rodent treadmill (Columbus Instruments), for a period of 40min per day at about 50% of the maximal exercise tolerance (Hoydal et al., 2007). Rats were acclimatized to the treadmill for 1 week by walking daily for 40 min starting at a speed of 5 m/min with increments of 1 m/min/day. After this period of acclimatization rats were exercised daily for 4 weeks at 12m/min at an incline of 5° for the period of the study.

2.3. Pulse wave velocity measurement

The rats were anesthetized in a closed chamber with isoflurane. Anesthesia was maintained with 1.5% isoflurane (in 100% O2) by mask. Rats were positioned supine on a temperature controlled printed circuit board (THM100, Indus Instruments, Houston, TX) with legs and arms taped to incorporate electrocardiogram electrodes. Body temperature was maintained at 37 °C.

Doppler spectrograms of aortic outflow were acquired with a 2-mm diameter, 10-MHz pulsed Doppler probe (DSPW, Indus Instruments, Houston, TX). Thoracic aortic outflow was acquired at a depth of 4–6 mm with the probe placed to the right of the sternum. Abdominal aortic flow was captured at a depth of 4–5 mm. The nature of these waveforms was verified by comparison to characteristic aortic outflow waveforms. The distance separating the probe locations was also measured. Aortic PWV is calculated as the quotient of the separation distance and the time difference between pulse arrivals, with respect to the R-peak of the ECG. Data analysis of Doppler and ECG signals was done off-line using DSPW software from Indus Instruments.

2.4. Pressure–volume loops

Closed-chest pressure–volume (P–V) relationships were measured using a combined pressure–conductance Millar catheter (SPR- 838, 2.0 Fr) and the Aria combined pressure–conductance system (Millar). Rats were anesthetized with ketamine/xylazine (120mg/kg, 12 mg/kg; ketamine, xylazine, respectively), and a tracheostomy was performed for mechanical ventilation. The conductance catheter was inserted through the right carotid artery and advanced into the left ventricle (LV). A polyethylene catheter was inserted into the femoral artery for measurement of arterial pressure. In addition, a catheter was inserted into the femoral vein for administration of albumin solution. A 2 Fr Fogarty catheter was advanced through the femoral vein into the IVC. Left ventricular P–V relations were measured through preload reduction by transiently inflating the balloon. Hemodynamic measurements were performed as previously described in detail (Barouch et al., 2002Varghese et al., 2000). Cardiac preload was determined using left ventricular end-diastolic volume (EDV) and pressure (EDP). Myocardial contractility was determined as the peak rate of rise in LV pressure (+dP/dtmax) divided by instantaneous pressure (dP/dtmax-IP). The load-independent end-systolic elastance (Ees) calculated from the linear end-systolic pressure–volume relationship (ESPVR) fitted in the pressure range of 40 to 110 mm Hg. The effective arterial elastance, Ea, was calculated as the ratio of the left ventricular end-systolic pressure and the stroke volume. Ventricular to arterial coupling was assessed as the Ea/Ees ratio. Active diastolic relaxation was measured by peak −dP/dt (−dP/dtmin), and the time constant of ventricular relaxation (tau). The latter is derived from the mono-exponential equation describing the rate of fall of ventricular pressure (regression of dP/dt vs pressure), and is a well validated measure of the rate of diastolic relaxation (Gilbert and Glantz, 1989). Mean arterial pressure (MAP) was calculated from peak systolic pressure (Pmax) and pressure at dP/dtmax (P@dP/dt<span< a=""> style="font-size: 0.8461em; line-height: 1.6363em; position: relative; vertical-align: baseline; bottom: -0.25em; top: 0.25em;">max) with the equation MAP=P@dP/dt<span< a=""> style="font-size: 0.8461em; line-height: 1.6363em; position: relative; vertical-align: baseline; bottom: -0.25em; top: 0.25em;">max+(PmaxP@dP/dt<span< a=""> style="font-size: 0.8461em; line-height: 1.6363em; position: relative; vertical-align: baseline; bottom: -0.25em; top: 0.25em;">max)/3, which estimates the center of gravity of the analog triangular pressure waveform in each contraction. The total peripheral resistance index (TPRI) is derived from the ratio of MAP and cardiac output index (COI): TPRI=MAP/COI. Ejection fraction (EF) is derived from stroke volume (SV) and EDV as follows: EF=SV/EDV. The end-diastolic P–V relationship (EDPVR), an assessment of diastolic compliance, was determined from the end-diastolic P–V data obtained utilizing IVC occlusion. A nonlinear fit was used to characterize EDPVR, yielding the curve: EDP=C*e(K*EDV) where C and K are real value constants. End-diastolic pressure increases exponentially with respect to rate constant K as age- and treatment-dependent end-diastolic volume increases with higher loads in consecutive contractile cycles. K values depend on the instantaneous rise in pressure (P) over the increase in volume (V), ΔP/ΔV=1/compliance, and could be used to approximate ventricular stiffness and diastolic function. Characterizing the exponential power of the nonlinear fit for EDPVR, these K values are shown in Fig. 2A.

Fig. 2
Parameters of myocardial contractility including the load-independent measurement end-systolic elastance (Ees) are restored by exercise and Alagebrium: aging is associated with a large decrease in measures of contractility as seen in representative P–V ...

2.5. Statistical analysis

All data are presented asmeans±SD. Experiments were performed in either young, old, old ALT, old exercise or old ALT plus exercise animals, without conducting longitudinal experiments. One way ANOVA followed by a Student–Newman–Keuls post-test was used for group comparisons. A value of P<0.05 was considered significant.

3. Results

Hemodynamic parameters in young (Y) and old (O) rats, and the modulating influence of ALT and Ex, individually and in combination in O rats are outlined in Table 1. A total of two animals died during the study (one old in the ALT treated group and one old in the exercise group).

Table 1
Hemodynamic parameters in young (Y) and old (O) rats and the modulating effects of ALT and EX individually and in combination in O rats.

Heart rate (HR), MAP, COI/CI, SV, EF, ESP, dp/dtmax, −IP, −dp/dt and preload recruitable stroke work (PRSW) were all significantly decreased in O compared to Y animals. EDV, EDP and TPRI were significantly increased in O animals compared to Y. While ALT or Ex each caused partial but statistically significant improvement in age-associated hemodynamic perturbations, their combination resulted in a greater and more consistent improvement of these parameters (Table 1, column 2 vs. 5).

Fig. 1A illustrates representative P–V loops in a young and an old rat. The P–V loops are substantially shifted to the right in the old compared to the young rat. Moreover, the peak systolic pressure developed and the slope of the ESPVR are significantly attenuated. Fig. 1B illustrates the representative P–V loops at baseline in young and old rats and following ALT and Ex, individually and in combination in O rats. Again the P–V loops in Y and O rats are significantly different. ALT or Ex partially attenuates the influence of age but their combinations render a P–V relationship in O animals that is almost identical to that observed in Y rats.

Fig. 1
Representative traces of families of P–V loops from O and Y rats demonstrating differences in both ESPVR and EDPVR: (A). P–V loops were obtained using a combined conductance/manometric catheter. EDPVR and ESPVR were determined following ...

3.1. Systolic function

As illustrated in Fig. 2, and outlined in Table 1, there was a significant difference in all indices of systolic function in O compared to Y rats. All parameters of systolic function were restored in rats receiving both exercise and ALT such that the parameters were not statistically significantly different from Y rats. For example, dP/dtmax (Fig. 3A) was reduced by 37% in O vs Y rats consistent with depressed contractile function. Also, SV, a load dependent measure of systolic function was decreased in O vs Y rats but was significantly improved in O rats treated with ALT+Ex. In addition, Ees, the slope of the ESPVR (Fig. 3B), effective arterial elastance (Ea) and preload recruitable stroke work (PRSW), were significantly decreased in O rats. Remarkably, O rats who exercised and received ALT demonstrate a substantial restoration of contractility; animals who received either intervention alone also improved, but not to the same degree as the combined intervention (Table 1). Furthermore, there was a significant improvement of Ees and PRSW in rats receiving combined treatment consistent with an additive/synergistic effect of ALT and exercise on contractile function. Exercise, ALT, and combination therapy all improved EF significantly in old animals. However, these improvements remained lower than the normal EF in young rats. EF is a highly load dependent measure. Regardless of the increase in SV, the increase in EDV in O rats was such that a greater restoration of EF was not observed, even though EDV decreased with exercise and ALT toward the level of young animals. With regard to ventricular–vascular coupling, Ea was significantly decreased in O as compared to Y rats and was not significantly different in the O groups treated with Alt or exercise, but was significantly increased in the combined exercise and Alt group such that it was not different from Y. The Ea/Ees ratio, a metric of the efficiency of coupling between the ventricle and vasculature, was not significantly different across all the groups suggesting that efficient coupling is maintained in all groups.

Fig. 3
Combination of exercise and Alagebrium improves parameters of diastolic function in old rats: old rats demonstrate an increase in the slope of the non-linear EDPVR (increased diastolic stiffness). In addition, parameters of active ventricular relaxation ...

3.2. Diastolic function

All indices of diastolic function were significantly impaired in O compared to Y rats including EDV and EDP (Table 1). The P–V loops were shifted to the right in O rats compared to Y. This is accompanied by an increase in the slope of the EDPVR in the old rats compared to the young (Fig. 3A). Indices of ventricular relaxation were also altered. Tau (the time constant of relaxation) (Fig. 3B) and −dP/dTmin (Table 1) were significantly decreased in O vs Y rats. Old rats treated with a combination of ALT and Ex demonstrated significant improvement in indices of diastolic function such that these indices were similar to that of Y control rats. Old animals treated with ALT alone, did not demonstrate a significant improvement in active relaxation (tau) but showed significant improvement in −dP/dtmin (Table 1). Animals that underwent exercise alone had a significant improvement in EDP.

3.3. Vascular stiffness

We used PWV as an in vivo measure of vascular stiffness. As illustrated in Fig. 4, PWV was approximately doubled in O rats compared to Y. Both ALT treatment and exercise alone resulted in an equal and significant decrease in PWV in O rats. Remarkably, the combination of exercise and ALT resulted in a further substantial decrease in PWV such that this parameter was not statistically different to that observed in Y rats. This outcome is consistent with a significant impact of combined exercise and ALT on large artery compliance.

Fig. 4
Age is associated with a substantial increase in vascular stiffness as measured by an increase in the pulse wave velocity (PWV). Stiffness is improved with Alagebriumor exercise and by the combination. (*) P<0.01 vs. Y; (#) P<0.01 vs. ...

4. Discussion

We have demonstrated for the first time that the combination of exercise training with the AGE crosslink breaker Alagebrium has a synergistic effect and significantly improves the parameters of both systolic and diastolic functions, and decreases vascular stiffness in a rat model of aging.

Our observations in old rat hearts are consistent with previous studies on aging (Boluyt et al., 2004Chang et al., 2004Raya et al., 1997Rozenberg et al., 2006Walker et al., 2006) and those of Pacher et al. (20042002) who demonstrated significant impairments in systolic performance, and in diastolic relaxation and stiffness in ~24 month old Fischer 344 rats. Additionally, we have demonstrated that effective arterial elastance (Ea) is decreased in O rats and is restored toward that of Y with exercise and Alt. Furthermore Ea/Es ratio is modestly decreased in O rats and restored to Y value in the O rats treated with a combination of exercise and Alt. This suggests that the combined intervention restores optimal ventricular–arterial coupling. This finding is somewhat consistent with Chang et al. (2004), who have also demonstrated that aging is associated with a decrease in Ea, that Ea is partially restored with the inhibition of AGE. While we found no statistically significant effect of ALT alone on these parameters, we did however observe similar trends. The differences may be accounted for by the difference in AGE crosslink breaker used (Aminoguanidine vs. ALT) or the dose administered.

It is now well accepted that aging in humans is associated with a significant rise in vascular stiffness which causes a significant increase in left ventricular systolic wall stress (for review see Kass, 2002). Effective arterial elastance (Ea) is coupled to an increase in ventricular stiffness (Ees) maintaining myocardial efficiency at near normal levels. This increase in Ea in aging humans is in contrast to the findings in the rat aging model (Chang et al., 2004Pacher et al., 2004). This discrepancy is explained on the basis of a markedly reduced stroke volume and therefore blood pressure in the O rats, despite an increase in central vascular stiffness. Efficient coupling is however maintained in this rodent model.

Acute changes in Ees are generally interpreted to represent changes in contractility while chronic changes, specifically increases, are indicative of alterations in chamber geometry and structure of the heart. In contrast, dP/dtmax, a contractility specific index, is not altered with aging in humans who in general demonstrate an increase in Ees. In aging humans diastolic dysfunction is the predominant feature, but systolic dysfunction can also develop, albeit perhaps at a later stage, in the disease process.

One of the interesting observations in this study is that ALT alone significantly improved the parameters of active myocardial relaxation as reflected by a decrease in tau. In addition, there was a significant improvement in the parameters of contractility as reflected by an increase in dp/dtmax. These observations suggest that ALT may have effects that modulate the molecular processes involved in active contraction and relaxation. It has recently been demonstrated that glycated proteins stimulate reactive oxygen species production in cardiac myocytes by an NADPH oxidase-dependent mechanism (Zhang et al., 2006). It is well established that not only does NADPH-dependent ROS production mediate myocardial hypertrophy, but it also leads to depressed myocardial contractility and impaired active relaxation. Thus, ALT may improve these parameters by preventing this process. The improvement in active relaxation with ALT may be particularly important for aged humans since even life-long and extensive exercise does not normalize measures of dynamic relaxation (Prasad et al., 2007).

Another interesting observation relates to the decrease inHR seen in O vs Y rats. This depressed HR is restored in ALT+Ex treated rats. Previous studies support a decrease in intrinsic heart rate (following sympathetic and parasympathetic blockade) in vivo in aging rats (Irigoyen et al., 2000) and humans (Jose and Collison, 1970). This has been confirmed in isolated spontaneously beating rat hearts (Friberg et al., 1985). Another possibility is amore profound depth of anesthesia in old rats compared to young rats, as there is a decrease in minimum alveolar concentration (MAC) of volatile anesthetics in old animals compared to young. Prior studies, however, demonstrated similar depressions of heart rate and blood pressure in old rats despite the use of different anesthetic techniques (Capasso et al., 1990Pacher et al., 2004). Additionally there is evidence supporting the concept that a significant age-related impairment in baroreflex control of HR and sympathetic nerve activity occurs (Lakatta, 1993). These changes are likely to have significant implications for age-related alterations in cardiovascular regulation. It is unclear from this study why combined Ex and ALT therapy might restore HR toward that of the young. One potential explanation is that exercise might improve baroreflex control of HR in old rats. Alternatively, ALT might decrease central vascular stiffness and in that way alter the sensitivity of the carotid baroreceptor “rheostat,” restoring baroreflex sensitivity.

There is increasing evidence that exercise attenuates age-associated diastolic dysfunction in animals (Brenner et al., 2001Starnes et al., 2003) and humans. For example, sedentary aging results in a large increase in LV diastolic stiffness compared to young but similarly sedentary subjects (Arbab-Zadeh et al., 2004). In contrast, master athletes had normal P–V relations compared to young controls, and similarly normal stress–strain curves demonstrating conclusively that life-long exercise (more than 2 decades in this study) preserves ventricular compliance (Arbab-Zadeh et al., 2004). While the effect of a lifetime of exercise on maintaining ventricular compliance is well established, until recently the effect of exercise training starting later in life remains unknown. Dr. Levine and coworkers have recently demonstrated that 1 year of endurance training had little effect on ventricular compliance in previously sedentary seniors (Fujimoto et al., 2010). On the other hand, there was a significant improvement in ventricular–vascular coupling. Interestingly, this is consistent with our observations in the exercised but not ALT treated rats. EDP and EDPVR were only modestly altered by exercise in contrast to the significant effect of exercise on vascular stiffness.

The large increase in vascular stiffness observed and its secondary effects on the heart (VVC) in the old rats are consistent with what has been previously described by our group and others (Atkinson, 2008Kim et al., 2009Santhanam et al., 2010Soucy et al., 2006). Furthermore, the significant improvement in vascular stiffness, as measured by PWV, in the animals who received either exercise or ALT, and the improvement in the group that received both interventions, are consistent with the proposed biologic effect of each intervention and our original hypothesis: a physiologically meaningful interaction between the two interventions. The increase in vascular stiffness with age results from a number of interacting/underlying mechanisms involving all the components of the vascular wall including the endothelium, structural proteins, vascular smooth muscle and intercellular matrix. The accumulation of AGE in the matrix contributes to vascular stiffness changes with aging. In animal studies, Alagebrium improved vascular and ventricular properties (Asif et al., 2000Candido et al., 2003Liu et al., 2003Vaitkevicius et al., 2001) and in one of the first human trials, ALT decreased pulsatile load as measured by pulse pressure and increased vascular compliance (Kass et al., 2001). Additional studies demonstrated improvement in left ventricular diastolic filling, quality of life, decreased left ventricular mass, left ventricular ejection and reduced aortic stiffness (Little et al., 2005Liu et al., 2003), while another trial failed to demonstrate significant improvements in cardiac function, or systolic blood pressure with ALT administration without exercise (Hartog et al., 2011). In a large double-blind multicenter trial, ALT was compared to placebo for the treatment of hypertension in patients with and without hypertension (SAPPHIRE and SILVER studies) (Bakris et al., 2004). The primary outcome (drop in systolic blood pressure by 5 mm Hg) was not achieved in this study, however ALT decreased systolic blood pressure by 2–3 mm Hg more than the placebo group. These results are unfortunately difficult to interpret as all groups (both ALT and placebo) had a significant drop in blood pressure of 6–10 mm Hg during the first 2 weeks of the study (Bakris et al., 2004). Currently, there is no clear evidence that ALT alone has lesser or more profound effects in humans than in rodents. Furthermore, there are no human studies that have investigated the combined effect of ALT and exercise on vascular stiffness. It should also be noted that at least in theory, AGEs could de-stabilize the fibrous cap of an atherosclerotic cap pre-disposing to myocardial infarction. However in the more than 1000 subjects studied in clinical trials of Alagebrium to date, there has been no signal of increased myocardial infarction or death. Longer trials of this agent involving a full year of therapy in otherwise healthy seniors are currently ongoing (clinicatrials.gov NCT01014572) and will be necessary to ensure safety of this agent.

Although others have demonstrated a significant effect of ALT in spontaneously hypertensive aged rats (Susic et al., 2004), this study represents the first demonstration of the synergistic effects of ALT in combination with exercise in a purely aging model. Exercise has also been shown to improve vascular characteristics. For example, Tanaka et al. have demonstrated that the predicted age-related increase in central arterial stiffness did not develop in physically active women (Tanaka et al., 19982000). Our data demonstrates a significant improvement in vascular stiffness in old exercised rats compared to age-matched sedentary controls. This observation is consistent with the idea that exercise can improve vascular properties.

What is the underlying mechanism contributing to the exercise and ALT-mediated reduction in vascular stiffness? Vascular stiffness is determined by dynamic (the vascular smooth muscle tone) and structural properties of the vascular wall. NO may regulate vascular stiffness both by acutely altering the tension developed by vascular smooth muscle cells, and by modifying the structure of blood vessels via its effects on vascular matrix protein characteristics (Wilkinson et al., 2004). There is emerging evidence that exercise can improve vascular properties by NO-dependent mechanisms. For example, in rats exercise increases the expression of NOS in the aorta and skeletal muscle arterioles (Spier et al., 2004Tanabe et al., 2003). In humans, exercise increases NOS phosphorylation and thereby NO signaling (Hambrecht et al., 2003). In addition to promoting vascular remodeling, exercise causes activation of mechano-transduction mechanisms in both endothelial and vascular smooth muscle cells, which result in: 1) stimulation of signaling pathways that up-regulate genes which promote anti-atherogenesis, eNOS expression and phosphorylation, and NO bioavailability, 2) up-regulation of anti-oxidant mechanisms (e.g. superoxide dismutase (SOD)), and 3) potentiation of anti-inflammatory mechanisms (Fukai et al., 2000Gielen et al., 2005Hambrecht et al., 2003Kojda and Hambrecht, 2005). This may further explain the findings by Guo et al. that ALT contributes to oxidative stress reduction by up-regulating activities of SOD and glutathione peroxidase (Guo et al., 2009).

There are a number of potential limitations of this study. We have been unable to measure AGE or RAGE receptors in cardiac tissue using immunohistochemical staining and biochemical assays. This would allow us to confirm that the mechanism by which ALT and Ex are working depends on its crosslink breaking activity. Additionally, we do not have measures of LV mass pre- and post-treatment (or any other echocardiographic data) in order to determine whether ALT cross-link breaking activity alters ventricular structure or wall thickness, and exercise capacity and catecholamine levels were also not measured. Some past studies have questioned the validity of measuring absolute ventricular volume via conductance catheters (Boltwood et al., 1989) (for a detailed review, see Burkhoff, 1990). These studies found that the offset volume is not constant but rather varies with loading conditions and stroke volume appears to be inconsistent if measured by ventriculography vs. a conductance catheter. However, the studies lack adequate validations utilizing sonomicrometry and ventriculography to measure a broad range of left ventricular volumes. At this point conductance catheters still provide accurate measurements during the cardiac cycle against which new methods are compared. Furthermore, conductance catheters offer the advantage of obtaining a continuous signal without the need to invade the chest cavity (Burkhoff, 1990Kottam et al., 2011). An additional limitation is that PWV was not adjusted for either heart rate or blood pressure, both of which can theoretically change the measured value for PWV without affecting the underlying arterial wall properties. Currently there is no clear consensus in the literature regarding the association of heart rate and pulse wave velocity. While some studies demonstrate an association between PWV and heart rate (Amar et al., 2001Sa Cunha et al., 1997), others fail to show this effect (Blacher et al., 1999Nurnberger et al., 2003Papaioannou et al., 2008). Despite these limitations, our physiologic measurements confirm the salutatory effects of the intervention on both systolic and diastolic functions in the aging rat heart. Lastly there is ongoing debate on the role of exercise intensity on improving the cardiovascular status (Cameron and Dart, 1994Hoydal et al., 2007Kemi et al., 2005). Our model of continuous moderate exercise resembles the regime mostly practiced and recommended for adults to improve cardiovascular function (Cameron and Dart, 1994). Recent animal studies however indicate that high intensity aerobic interval training might be more efficient at improving the cardiovascular status (Hoydal et al., 2007Kemi et al., 2005).

In summary, exercise and ALT in combination improve diastolic stiffness, systolic and diastolic dysfunctions, LV contractility and large artery compliance in a rodent model of aging. This result may have important therapeutic implications for the aging population if it can be confirmed along with its safety profile over a longer period of time in seniors. Further studies extending these results to humans would seem warranted.

 

Picture          Picture

 

----------------------------------------------------------------------------------------------------------------------------------------------------------

*** SPECIAL NOTE FROM DR. WICHMAN ***

The following excellent article is reproduced from the Journal of Medical Physics at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804148/:

 

J Med Phys. 2009 Jan-Mar; 34(1): 43–47.
PMCID: PMC2804148

Infrared thermal imaging for detection of peripheral vascular disorders

 

Introduction

The correlation of body temperature and diseases has been known for centuries, but in recent years, due to advent of new technologies, skin temperature has been used as a convenient and effective diagnostic tool to detect diseases.[12] Human body temperature has been recorded with thermocouples, thermistors, and thermopiles, for almost 60 years, and these sensors are very large in size, slow in response, and difficult to attach to the skin.[3] The first documented application of thermography was a method of research for early preclinical diagnosis of breast cancer in the year 1956.[4] Infrared thermography or infrared imaging or thermal imaging is a non-contact tool, which maps the surface temperature of a body or an object and it has a wide range of applications starting from condition monitoring in industries to medical imaging.[59] Medical infrared thermal imaging has been used to study the flow of blood, the detection of breast cancer, and muscular performance of the human body.[10,11] Thermal images have been used to quantify sensitive changes in skin temperature in relation to certain diseases.[12] Blood flow can be assessed by many methods including the washout technique, laser Doppler flowmetry,[13] and medical infrared thermal imaging.[14] Of these, infrared thermography has the advantages of being noninvasive,[15] fast, reliable, with non-contact, capable of producing multiple recordings at short time intervals, and absolutely safe for patients and doctors. In all these studies, only the relative and not absolute temperatures are significant and the relative temperatures have to be measured at many points on the skin, and in this sense, the Infrared (IR) sensing device has many advantages over conventional devices.[16,17] IR radiation covers a wavelength that ranges from 0.75μm to 1000μm, among which the human body emissions that are traditionally measured for diagnostic purposes occupy a narrow band of wavelengths ranging from 8μm to 12μm. This region is also referred as the long wave IR (LWIR) or body infrared rays. Another terminology that is widely used in medical IR imaging is thermal infrared (TIR), where the wavelength is beyond 1.4μm. Within this region, the infrared emission is primarily heat or thermal radiation. The image generated by TIR imaging is referred to as thermogram. The near infrared (NIR) region occupies wavelengths between 0.75μm and 1.4μm. Although the NIR and mid-wave IR (MWIR) regions are not traditionally used in human body screening, the new generation detectors enable the use of multispectral imaging in medicine, in which these regions are observed in different diagnostic cases.[18,19] The fundamental equations that link the absolute temperature of the object with the intensity and wavelength of the emitted radiation are given by the Planck's, Stefan Boltzmann, and Wein's Displacement law.[20] The energy radiation after Stefan Boltzman law is W = ɛ σ T4, where ɛ is the emissivity and T the absolute temperature. The emissivity (ɛ) of a material is the ratio of energy radiated by a particular material to the energy radiated by a black body at the same temperature. It is a measure of a material's ability to radiate absorbed energy. A true black body would have an emissivity value of unity (ɛ = 1), while any real object would have ɛ < 1. Emissivity depends on factors such as, temperature, emission angle, and wavelength. For a black body the total heat energy radiation is proportional to T4. A perfect black body is a perfect emitter and a perfect absorber for all wave length energies radiated, depending on the temperature of the material. Human skin keeps the body temperatures normally at 37°C. When the skin is in cooler surroundings, it cools down, emitting heat. Similarly when skin is in warmer surroundings, it absorbs heat making the body adjust itself by sweating, to keep the temperature at 37°C. In both situations, therefore, the skin acts like a black body with emissivity of 0.98, as observed. It has been shown that the emissivity of skin (black, white, burnt, male, and female) independent of the wavelength and its value is close to 0.98.[2123] Therefore, human beings can be treated as true black bodies. The infrared radiations from the object are converted using a suitable IR detector and displayed as color or black and white image. The colors are simply a visual aid to show the temperature differences at different regions in each image.[24] Medical infrared diagnostics uses the fact that many pathological processes in the human organs manifest themselves as local changes in heat production and also as changes in the blood flow pattern of the affected organs or tissues. Infrared thermography involves recording a sequence of thermograms at several stationary positions of the human being, inspected in his natural condition. Focal plane array (FPA) based systems are more efficient for medical applications than systems previously using single element detectors.[2527] In clinical diagnostics infrared imaging is used as a physiological test that measures the subtle physiological changes that might be caused by many conditions, e.g., contusions, fractures, burns, carcinomas, lymphomas, melanomas, prostate cancer, dermatological diseases, rheumatoid arthritis, diabetes mellitus and associated pathology, deep venous thrombosis (DVT), liver disease, bacterial infections, etc. These conditions are commonly associated with regional vasodilation, hyperthermia, hyperperfusion, hypermetabolism, and hypervascularization[18] which generate a higher-temperature heat source. The heat emanating onto the surface from the heat source and the surrounding blood flow can be quantified by using the Pennes' bio-heat equation, as follows,

2cbwb(TTa)+qm=0
(1)

Where k is the conductivity, qm is volumetric metabolic rate of tissue, is the product of the specific heat capacity and the mass flow rate of blood units per volume of tissue, T is the unknown tissue temperature, and Ta is the arterial temperature.[21]

Materials and Methods

The patients were allowed to rest in a room where relative humidity and room temperature were controlled (to achieve equilibration body temperature with the ambient temperature). No parts of the patient were in contact with any hot or cold sources. Only a minimum number of persons were allowed inside the room. The patients were kept away from air convection sources. These precautions had been taken to minimize the variables that might influence temperature measurement.

The main objective in the preparation of the above protocol was to ensure all the variables that might have influence during thermal image were fixed. The patient was thoroughly examined by a team of doctors and a clinical report was recorded. Patients undergoing examination by thermal imaging were disrobed in the affected region for 15 minutes, in the room. A wall–mounted, air-conditioning unit provided the required temperature inside the room. The infrared thermal camera was positioned 1 m away from the affected portion of the patients and healthy volunteers. Standard views were taken with the camera mounted on a tripod stand. The regions of interest were the anterior, posterior, and lateral views. The same views of the corresponding contra-lateral region of the patient and of normal controls were also taken. The same region was continuously monitored on a color display unit with pseudo color, making temperature changes easily discernible.

Thermal imaging of the patients was carried out using the Thermovision-550 system. This is a compact lightweight focal plane array based system with a temperature resolution of 0.1K. A high-resolution color image is provided in real time, which can be viewed on a miniature screen provided with the system or by using an external monitor. The image is captured and stored in the removable PC-card. The surface temperature profiles of the patients are recorded and later analyzed using the IRWIN software. The thermal profile of the area of examination is compared with the counterpart region of the same subject and the same region of a healthy volunteer. Using the spot meter, area, and profiling tools, the change in temperature in the region of interest is determined.

Results and Discussions

Case 1

A 28-year-old male, with a history of pain in the left lower limb, which was getting aggravated on prolonged standing, was examined using thermal imaging. He had varicosity of the long saphenous system of the left lower limb. The patient was suffering from complications of varicosity for the past one year. He was using crepe bandages.

The patient was febrile and comfortable at rest and was not a smoker or user of alcohol. The respiratory system (RS), cardiovascular system (CVS), central nervous system (CNS), and per abdominal examinations were normal. Local examination of the lower limbs showed dilated veins present in the dorsal aspect of the foot, extending up to the lower one-third of the leg on the right lower limb. There were dilated tortuous veins in the dorsum of the foot in the left lower limb. The radial pulse, carotid pulse, dorsalis pedis, and posterior tibial pulse were normal.

Figure 1a and and1b1b show the thermal image and photograph of the affected patient's left leg. The line profile inset in Figure 1a shows the temperature profile along the toe tips. From the thermal image shown in Figure 1a, it can be clearly seen that a lower temperature is noted at the distal portion (indicated by white arrow in Figure 1a). This is probably due to sluggish blood circulation in the toes and venous drainage being inadequate due to the varicosity. In the patient, the area outlined by a black line, i.e., the demarcated dark-green patches, and a blue line, i.e., the demarcated pale-green color patch [Figure 1a] show abnormal temperatures compared to the temperature of the surrounding area of the same patient's leg and to that of a normal person's leg. The temperature in these marked regions is, on an average, 0.7 to 1°C above the normal regions. The abnormal temperature is due to varicose veins, with probable mild inflammation, which was not evident on clinical examination. The human body creates heat through the metabolic activity, which is the basic reaction of life. The blood in the near-surface veins, heats the surface more than the normal veins and arteries. Localized elevated temperatures are easier to discern when the person is in a cool room for at least 20 minutes. A uniform temperature can be seen in the leg of a normal person.

Figure 1
(a) Isothermal image and (b) Photograph of the affected patient's leg

Case 2

A 31-year-old male, who has a history of swelling in both the lower limbs on prolonged standing, for five years, had recurrent ulceration over the left lateral malleolus, associated with pain and discharge of pus. The patient underwent treatment and surgery four years back, for the same complaint. The RS, CVS, CNS, and per abdominal examinations were normal. Local examination of the left lower limb showed tortuous dilated veins, recurrent healing ulcers on the left lateral malleolus, ulcers covered with slough and pus discharge. Old healed scars were about 8 × 1 cm in length, present in the medial aspect of the lower limb. In the right lower limb, dilated tortuous veins, mild edema over the right ankle joint, and also old healed scars were noticed. The palpable arterial pulse was normal. The patient had systemic hypertension noted six months ago and he was under medication for the same.

Figure 2a and and2b2b show the dorsal thermal images and photograph of the affected patient's left leg. Clinically detected areas with varicosity show up as areas of increased warmth in the thermal images. From the thermal images, the warm areas are noted on the lateral side of the left leg as well, an unusual finding, because most patients have varicosity located only on the medial side of the leg. The distal region near the toes seems to be dark or with lower temperature due to the poor perfusion of blood (indicated by a white arrow in Figure 2a, and is attributed to stasis of circulation due to varicosity.

Figure 2
(a) Isothermal image and (b) Photograph of the affected patient's leg (Dorsal view)

Areas outlined by black lines, i.e., the demarcated dark-green patch and blue line, i.e., the demarcated pale-green color patch in Figure 2a show abnormal temperature compared to the temperature of the normal person's leg, for the same region. The demarcated area in the thermal image shows a higher temperature due to the tortuous venous carrying warm blood at a sluggish speed when compared to normal venous drainage and probable mild inflammation in those areas. The temperature changes as noted on the patient are not seen in the leg of the normal person.

Case 3

A 48-year-old male has had pain in the left leg (calf muscle) for the past two years. The pain has been severe for the past six months. He has had a history of pain aggravation on walking and pain being relieved by rest. On prolonged standing the pain increased. The RS, CVS, CNS, and per abdominal examinations were normal. The upper limb pulses were felt normally in the right and left lower limbs, the dorsalis pedis was normal in the right, with feeble low volume in the left lower limb, and the posterior tibial pulse was normal on the right, with low volume on the left. The patient is an occasional smoker and user of alcohol. There was an injury in the left big toe eight months ago. He had a nonhealing ulcer on the left great toe and gangrenous tissue was found on the great toe.

From the thermal images, the left leg medial view of the patient shows elevated temperatures because of thrombosis, a condition marked by blood clotting within the blood vessels. This disease may be potentially life threatening if dislodgment of the thrombus results in pulmonary embolism. It may be burger disease because of arterial insufficiency. It is an arterial obstruction. The clinically recorded information shows severe pain in the calf muscle, the area represented in the thermal image as a warm area shows abnormal temperature compared to the temperature of the normal person's leg, for the same region. These temperature changes are not seen in the thermal image of the normal person's left leg.

Case 4

A 40 year-old-male had a swelling in the little finger of the left hand that was two months old. The swelling was present with a pricking type of pain and pus discharge from the left ring, middle, and index fingers. Pain was radiating from the left hand and forearm to the left chest and distal phalanges. The RS, CVS, CNS, and per abdominal examinations were normal. Local examination of the patient's right upper limb was normal. The left upper limb on inspection showed gangrenous swelling with inflammation in the left little, ring, middle, and index fingers. There was purulent discharge from the nail beds that had a foul smell. There was hyperpigmentation present in the left palm. The patient was a smoker for the past 10 years (10 – 15 beedis per day), and an occasional user of alcohol. He has no history of any surgery in the past. Due to pain he was unable to sleep and has had a reduced appetite.

From the thermal images it is clearly seen that the temperature of the finger tips of the left hand is cooler than the normal body temperature, which may be attributed to vascular insufficiency. These abnormalities are due to ischemic necrosis (death of tissue affected by local injury due to loss of blood supply) of the distal phalanges. It can be seen that the temperature increase in the affected person's hand was almost 1.5°C compared to the normal hand.

Conclusions

Thermal imaging has been successfully used for medical diagnosis of vascular disorders. The temperature in the affected regions of patients with vascular disorders was low in the extremities due to obstructed arteries. However, in some areas it showed 0.7 to 1°C higher temperature than the normal areas due to inflammation and venous flow alteration. In general the thermal image findings were in good agreement with the clinical findings. However, the areas showing higher temperature contrast were noted not to be obvious in the clinical examination. This study demonstrates the usefulness of thermal imaging for medical diagnostics, with high reliability.


Articles from Journal of Medical Physics are provided here courtesy of Medknow Publications
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Thermography or infrared thermography (IRT) uses infrared rays to create an image of the body. This non-invasive procedure maps the body’s surface temperature which can be used to diagnose potential and existing medical issues such as breast cancer, diabetes, neuropath and vascular disorders.

Some diseases cause variations in body temperature, which produce colored patterns on a monitor. The doctor interprets each pattern to diagnose issues and then follow up with further testing or treatment.

External Counter Pulsation – A Non-invasive Therapy for Chronic Angina

What is Angina?

Angina is a signal from your body telling you that your heart muscle is not receiving enough oxygenated blood.Over 6 million people in the United States suffer from this condition.The heart requires an especially enriched supply of oxygen via the incoming blood flow in the coronary arteries. When the vessels that supply the heart with oxygenated blood become narrowed, the area of the heart that is not receiving the proper blood flow responds with a very painful signal called angina pectoris.

How Can External Counter Pulsation (ECP) Relieve Angina?

Your heart is the pump that supplies blood flow throughout the body. It supplies tissues with the oxygen and nutrients that are needed to sustain life. In order to efficiently accomplish this important task, the heart muscle needs oxygen-enriched blood to generate energy for pumping blood to the body. The heart relies on its own set of blood vessels called coronary arteries to receive oxygenated blood.ECP seems to improve circulation to your heart muscle by opening new pathways that circumvent the blocked arteries.

ECP Benefits:

  • Less medication is required
  • Fewer angina attacks
  • They can do much more physically such as walking, golfing and gardening
  • Life becomes more normal

This page is under construction. If you would like to know more about this topic, please call 770-232-7883 or contact us by This email address is being protected from spambots. You need JavaScript enabled to view it..

 

PlaqueX is used to repair damage to cell membranes and can reduce fatty deposits and plaque in blood vessels. PlaqueX, also known as phosphatidylcholine, is a lipid (a type of fat cell) comprises part of the cells membrane. LDL cholesterol exists in this two layer membrane to assist in cell stability.

Age can damage the cell membrane which leaks LDL cholesterol into the blood stream. Also catheters can damage the cell membrane as well. To repair this damage, phosphatidylcholine can be administered to help normalize LDL levels in the cell. The cell membrane is strengthened damage to blood vessel repaired.

N-Acetyl Cysteine, a derivative of the amino acid L-cysteine, is often used to treat liver failure caused by Acetaminophen overdose or as a mucus thinner to manage angina, colds, the flu and cystic fibrosis. However, research has found that N-Acetyl Cysteine can be used an anti-inflammatory and antioxidant.

Because of its ability to reduce inflammation in the airways, it’s been studied as a treatment for COPD and types of lung disorders. As an antioxidant, it reduces oxidative stress in the body, which then allow cells to repair damage.

Sources and Research:
N-acetylcysteine expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic acid-induced colitis in rats.

Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients

--------------------------------------------------------------------------------------------------------------------------------

*** SPECIAL NOTE FROM DR. WICHMAN ***

We refuse to add "fluff" to our Chelation formula.  Beware of doctors who insist on mixing Vitamin C with Chelation.  Ascorbate reacts with the EDTA/iron complex to cause oxidative damage (http://chelation.me/wp-content/uploads/2016/02/Free-Rad-Vit-C-5-05.pdf).  Just because these doctors are copying someone else's protocol is NO EXCUSE!

----------------------------------------------------------------------------------------------------------------------------------------------------------

 

Heavy Metal Poisoning Damages the Heart, Arteries, Kidneys & Liver

Heavy metal poisoning is one of the most insidious means of wrecking personal health and creating strong feelings of poor health. Symptoms are wide-ranging and often debilitating. Scientific research has demonstrated that heavy metals, even in small amounts, can damage every organ and every system in the body.

Heavy metals have the ability to fool the body because they have the same chemical structure as helpful minerals. Because of this similarity, heavy metals are absorbed by the body. This allows these metallic toxins (such as mercury, nickel, lead, arsenic, cadmium, aluminum, platinum, and copper) to enter the cell and stay there. Once inside the cell, the heavy metals block metabolic processes such as nourishing and detoxifying cells.

Often, these heavy metals accumulate in the arteries, heart, liver and kidneys – our most vital organs.

Heavy Metal Poisoning may be a factor in most heart diseases, but other symptoms and problems include:

  • Abdominal pain
  • Psychological problems
  • Fatigue
  • Shortness of breath
  • Cardiovascular problems
  • Liver and Kidney Damage
  • Poor complexion and Skin Discoloration
  • Breathing problems
  • High Blood Pressure
  • High Cholesterol

Exposure to heavy metals com from a variety of sources, including air pollution, heavy metal tainted seafood, industrial runoff, pesticides, mercury dental fillings, tap water, lead-based paints and commercially raised meats.

Chelation Therapy Removes Heavy Metals from Your Body

Chelation IV Therapy introduces a Chelator that chemically binds with heavy metals to create an inert compound. This intert compound is eliminated via all excretory organs. The therapy increases the blood flow through the entire body, strengthens the heart and all body organs and systems.

This therapy is administered by our staff of registered RN’s and specialists and is done in our clinic.

The results are improved blood flow, decreased heavy metal toxicity and healthier organs.

More Information About Heart Disease and Chelation Therapy

Heart Disease

Heart disease kills more people in the US than other disease. Approximately one million Americans die each year from such cardiovascular diseases as heart attack, hardening of the arteries, irregular heart beat, high blood pressure, stroke, rheumatic heart disease and congestive heart failure. That”s twice as many deaths as from cancer and 25 times as many from AIDS. And nearly one in four Americans have some form of heart disease right now.

The heart can be weakened or injured by a variety of different means. Toxic chemicals that enter our bodies from processed foods, air and water pollution, pharmaceuticals, and household chemicals enter the bloodstream and can make artery walls sensitive and irritated. Acidosis (too much acid in the body) can corrode the cellular membranes of the heart, arteries, and the veins.

 

This irritation of tissues that make up the heart, heart valves, arteries, and veins causes the body to respond by building a protective coating along these irritated areas. This protective layer is often composed of calcium. Calcium in the protective layer then combines with fat, cholesterol, and scar tissue into a hardened arterial plaque known as atherosclerosis.

Additionally, the elasticity of the heart and arteries can be weakened by these chemicals so that the arteries become hard. This is known as hardening of the arteries.

Understanding the Problem

According to renowned Swiss cardiovascular researcher Dr. Walter Blumer, vascular diseases may be initiated by heavy metals. Heavy metal toxicity can cause such conditions as aortic arteriosclerosis, hypertension and kidney failure. As updated research says, for example, “vulnerable plaque” inside the blood vessels is created because of heavy metal toxicity and bacterial infections.

To explain shortly, when heavy metal toxicity exposure happens, immune system goes down, body loses balance, bacteria starts to multiply, soft plaque of cholesterol is formed, body reacts to bacteria and soft cholesterol plaque as an inflammation. Body reacts by attacking it with defensive white blood cells. The Test, called C-Reactive Protein(CRP), shows systemic inflammation.

One of the reaction of the body to the inflammation is to do hyper coagulation, possibly within soft cholesterol plaque, which creates thrombus, or “vulnerable plaque.”

What is “vulnerable plaque”?

Recent scientific research has pointed to a “silent killer” who has been hidden, the soft plaque, a thrombus, which is not picked up quickly, like hard calcified plaque by equipment because it can be at any part of the human body, and not necessarily in the examined part of the body. It is now suspected to be responsible for 85% of all heart attacks and strokes. This soft plaque has been given the rather strange, but unfortunately correct, name of “vulnerable plaque.”

How is “vulnerable plaque” formed?

Research in Switzerland spanning 40 years has indicated that this soft plaque predominantly forms within the walls of arteries as soft cholesterol. Dr. Gordon reports that as it grows it just barely extends beyond the walls into the artery, and develops a fibrous cap to cover this extension. The body interprets this condition as an infection and responds by attacking with defensive blood cells. This inflames the easily ruptured cap and cause portions to break off into the blood stream (thrombus). The soft plaque contains powerful coagulants that when released into the blood stream during breakage can form massive clots in the heart (leading to heart attack) or in the brain (leading to stroke.)

Why does “vulnerable plaque” form?

The latest research suggests that soft plaque is the result of extremely small bacteria and viruses, which we carry on without the problems until stress of toxic exposure happens to the body.

Bacteria eats these toxins, which come from environmental contamination in our bodies from all the artificial chemicals, that have been pumped into our air, the water and food and multiplies as a result. While some of these contaminants are organic molecules, the worst ones of all are the heavy metals.

Tests to Determine Heavy Metal Toxicity

Laboratory tests to determine if one has toxic levels of heavy metals include analyzing blood, urine, stool, and hair samples. Since heavy metals cause systemic inflammation in the circulatory system, one test that is now becoming a standard is called “C-Reactive Protein” (CRP) test. The November 25, 2002 issue of U.S. News and World Report spent an entire article describing and praising CRP testing as a critical means of determining the health of the human heart. CRP testing is important because it can show risk for cardiovascular disease where other standard test show none at all. This is because inflammation does not show up on the other standard tests, and CRP is associated with inflammation.

Therapies for Heavy Metal Toxicity

Dr. Blumer”s research demonstrated that chelation therapy is able to help eliminate heavy metals from the human body. Chelation is a procedure where CHELATOR (in our Clinic we use CaEDTA) is introduced into the body and chemically binds with heavy metals to create an inert compound. This Chelator is a wonderful blood thinner as well.This inner compound is eliminated via all excretory organs. The therapy increases the blood flow through the entire body, strengthens the heart and all body organs and systems. This therapy is combined with oral supplementations and detoxification therapies such as colon hydrotherapy and Far InfraRed Sauna. This heavy metal detoxification protocol helps to eliminate the unwanted heavy metals from the body via urination, defecation and perspiring and to support the immune system.

How does CaEDTA Chelation Therapy Work?

“As unbelievable as it may seem, it now appears that a rapidly infused, affordable, painless push of CALCITETRACEMATE (calcium) ethylenediaminetetraacetate (EDTA) may be the ideal therapy for mercury detoxification. EDTA is a chemical chelator, only having one main action, which is to chelate or bind minerals to it. Calcium EDTA is a chelating agent that gathers together ions of heavy metals and exchanges those with calcium. The edetate forms with the heavy metal, making a stable complex. The heavy metal becomes non ionic and consequently looses its toxicity. Then the compounded molecule is readily excreted by the kidney. – Garry Gordon, M.D., D.O.

Chelation Intravenous Therapy: The Intravenous Therapy is a wonderful method of supporting the entire body without involving the digestion process.

“Research has shown that there is a need for high concentrations of vitamins and minerals in the blood stream before we are able to see specific results. It has been found that some patients appear to require a high blood level for a short period of time to achieve certain benefits that can be achieved with nutritionally based therapy. Now, research is showing that this same principle applies to heavy metal detoxification, when EDTA administration is at its maximum.” Garry Gordon, M.D., D.O.

Heavy Metal Poisoning Damages the Heart, Arteries, Kidneys & Liver

Heavy metal poisoning is one of the most insidious means of wrecking personal health and creating strong feelings of poor health. Symptoms are wide-ranging and often debilitating. Scientific research has demonstrated that heavy metals, even in small amounts, can damage every organ and every system in the body.

Heavy metals have the ability to fool the body because they have the same chemical structure as helpful minerals. Because of this similarity, heavy metals are absorbed by the body. This allows these metallic toxins (such as mercury, nickel, lead, arsenic, cadmium, aluminum, platinum, and copper) to enter the cell and stay there. Once inside the cell, the heavy metals block metabolic processes such as nourishing and detoxifying cells.

Often, these heavy metals accumulate in the arteries, heart, liver and kidneys – our most vital organs.

Heavy Metal Poisoning may be a factor in most heart diseases, but other symptoms and problems include:

  • Abdominal pain
  • Psychological problems
  • Fatigue
  • Shortness of breath
  • Cardiovascular problems
  • Liver and Kidney Damage
  • Poor complexion and Skin Discoloration
  • Breathing problems
  • High Blood Pressure
  • High Cholesterol

Exposure to heavy metals com from a variety of sources, including air pollution, heavy metal tainted seafood, industrial runoff, pesticides, mercury dental fillings, tap water, lead-based paints and commercially raised meats.

Chelation Therapy Removes Heavy Metals from Your Body

Chelation IV Therapy introduces a Chelator that chemically binds with heavy metals to create an inert compound. This intert compound is eliminated via all excretory organs. The therapy increases the blood flow through the entire body, strengthens the heart and all body organs and systems.

This therapy is administered by our staff of registered RN’s and specialists and is done in our clinic.

The results are improved blood flow, decreased heavy metal toxicity and healthier organs.

More Information About Heart Disease and Chelation Therapy

Heart Disease

Heart disease kills more people in the US than other disease. Approximately one million Americans die each year from such cardiovascular diseases as heart attack, hardening of the arteries, irregular heart beat, high blood pressure, stroke, rheumatic heart disease and congestive heart failure. That”s twice as many deaths as from cancer and 25 times as many from AIDS. And nearly one in four Americans have some form of heart disease right now.

The heart can be weakened or injured by a variety of different means. Toxic chemicals that enter our bodies from processed foods, air and water pollution, pharmaceuticals, and household chemicals enter the bloodstream and can make artery walls sensitive and irritated. Acidosis (too much acid in the body) can corrode the cellular membranes of the heart, arteries, and the veins.

 

This irritation of tissues that make up the heart, heart valves, arteries, and veins causes the body to respond by building a protective coating along these irritated areas. This protective layer is often composed of calcium. Calcium in the protective layer then combines with fat, cholesterol, and scar tissue into a hardened arterial plaque known as atherosclerosis.

Additionally, the elasticity of the heart and arteries can be weakened by these chemicals so that the arteries become hard. This is known as hardening of the arteries.

Understanding the Problem

According to renowned Swiss cardiovascular researcher Dr. Walter Blumer, vascular diseases may be initiated by heavy metals. Heavy metal toxicity can cause such conditions as aortic arteriosclerosis, hypertension and kidney failure. As updated research says, for example, “vulnerable plaque” inside the blood vessels is created because of heavy metal toxicity and bacterial infections.

To explain shortly, when heavy metal toxicity exposure happens, immune system goes down, body loses balance, bacteria starts to multiply, soft plaque of cholesterol is formed, body reacts to bacteria and soft cholesterol plaque as an inflammation. Body reacts by attacking it with defensive white blood cells. The Test, called C-Reactive Protein(CRP), shows systemic inflammation.

One of the reaction of the body to the inflammation is to do hyper coagulation, possibly within soft cholesterol plaque, which creates thrombus, or “vulnerable plaque.”

What is “vulnerable plaque”?

Recent scientific research has pointed to a “silent killer” who has been hidden, the soft plaque, a thrombus, which is not picked up quickly, like hard calcified plaque by equipment because it can be at any part of the human body, and not necessarily in the examined part of the body. It is now suspected to be responsible for 85% of all heart attacks and strokes. This soft plaque has been given the rather strange, but unfortunately correct, name of “vulnerable plaque.”

How is “vulnerable plaque” formed?

Research in Switzerland spanning 40 years has indicated that this soft plaque predominantly forms within the walls of arteries as soft cholesterol. Dr. Gordon reports that as it grows it just barely extends beyond the walls into the artery, and develops a fibrous cap to cover this extension. The body interprets this condition as an infection and responds by attacking with defensive blood cells. This inflames the easily ruptured cap and cause portions to break off into the blood stream (thrombus). The soft plaque contains powerful coagulants that when released into the blood stream during breakage can form massive clots in the heart (leading to heart attack) or in the brain (leading to stroke.)

Why does “vulnerable plaque” form?

The latest research suggests that soft plaque is the result of extremely small bacteria and viruses, which we carry on without the problems until stress of toxic exposure happens to the body.

Bacteria eats these toxins, which come from environmental contamination in our bodies from all the artificial chemicals, that have been pumped into our air, the water and food and multiplies as a result. While some of these contaminants are organic molecules, the worst ones of all are the heavy metals.

Tests to Determine Heavy Metal Toxicity

Laboratory tests to determine if one has toxic levels of heavy metals include analyzing blood, urine, stool, and hair samples. Since heavy metals cause systemic inflammation in the circulatory system, one test that is now becoming a standard is called “C-Reactive Protein” (CRP) test. The November 25, 2002 issue of U.S. News and World Report spent an entire article describing and praising CRP testing as a critical means of determining the health of the human heart. CRP testing is important because it can show risk for cardiovascular disease where other standard test show none at all. This is because inflammation does not show up on the other standard tests, and CRP is associated with inflammation.

 

Dr. Blumer”s research demonstrated that chelation therapy is able to help eliminate heavy metals from the human body. Chelation is a procedure where CHELATOR (in our Clinic we use CaEDTA) is introduced into the body and chemically binds with heavy metals to create an inert compound. This Chelator is a wonderful blood thinner as well.This inner compound is eliminated via all excretory organs. The therapy increases the blood flow through the entire body, strengthens the heart and all body organs and systems. This therapy is combined with oral supplementations and detoxification therapies such as colon hydrotherapy and Far InfraRed Sauna. This heavy metal detoxification protocol helps to eliminate the unwanted heavy metals from the body via urination, defecation and perspiring and to support the immune system.

How does CaEDTA Chelation Therapy Work?

“As unbelievable as it may seem, it now appears that a rapidly infused, affordable, painless push of CALCITETRACEMATE (calcium) ethylenediaminetetraacetate (EDTA) may be the ideal therapy for mercury detoxification. EDTA is a chemical chelator, only having one main action, which is to chelate or bind minerals to it. Calcium EDTA is a chelating agent that gathers together ions of heavy metals and exchanges those with calcium. The edetate forms with the heavy metal, making a stable complex. The heavy metal becomes non ionic and consequently looses its toxicity. Then the compounded molecule is readily excreted by the kidney – Garry Gordon, M.D., D.O.

Chelation Intravenous Therapy: The Intravenous Therapy is a wonderful method of supporting the entire body without involving the digestion process.

“Research has shown that there is a need for high concentrations of vitamins and minerals in the blood stream before we are able to see specific results. It has been found that some patients appear to require a high blood level for a short period of time to achieve certain benefits that can be achieved with nutritionally based therapy. Now, research is showing that this same principle applies to heavy metal detoxification, when EDTA administration is at its maximum.” Garry Gordon, M.D., D.O.

 

Image result for carotid intima-media thickness

 

----------------------------------------------------------------------------------------------------------------------------------------------------------

*** SPECIAL NOTE FROM DR. WICHMAN ***

Dr. Wichman is a Board Certified Radiologist who specializes in Ultrasound.  He maintains a Philips/Atl HDI 5000 Ultrasound machine on site.  Capabilitites of this unit include: (1) Carotid Intima-Media Thickness (CIMT) evaluation; (2) Echocardiography; (3) Lower Extremity Doppler evaluation; (4) Brachial Flow-Mediated Dilation (FMD) test; (5) Tumor Mass assessment; (6) Gallbladder evaluation; (7) Ultrasound-Guided Needle placement; (8) etc.

----------------------------------------------------------------------------------------------------------------------------------------------------------

 

The carotid Intima-Media Thickness Test (CIMT) is a test that measures the thickness of the two layers of the carotoid artery to determine the risk of heart disease and stroke. The carotid artery has two layers, the intima and media, and increased thickness of these membranes is an indicator of carotid atherosclerotic vascular disease.

After performing the test, a doctor can diagnose and treat potential cardiovascular issues.

Sources and Research:
Common Carotid Intima-Media Thickness and Risk of Stroke and Myocardial Infarction

 

Image result for heart rate variability

 

----------------------------------------------------------------------------------------------------------------------------------------------------------

*** SPECIAL NOTE FROM DR. WICHMAN ***

For information regarding Heart Rate Variability (HRV) and Type 1 Diabetes, please read http://care.diabetesjournals.org/content/36/8/2351.

Also, the following excellent article is reproduced from ISRN Endocrinology at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521488/:

 

ISRN Endocrinol. 2012; 2012: 168264.
Published online 2012 Dec 4. doi:  10.5402/2012/168264
PMCID: PMC3521488

Cardiac Autonomic Neuropathy Measured by Heart Rate Variability and Markers of Subclinical Atherosclerosis in Early Type 2 Diabetes

 

1. Introduction

Cardiac autonomic neuropathy (CAN) is a serious complication of type 2 diabetes mellitus (T2DM) which carries an approximately 5-fold increased risk of mortality in these patients [12]. Damage to the autonomic innervations of the heart is a harbinger of dire outcomes such as lethal arrhythmias and sudden cardiac death [3].

Heart rate variability (HRV) analysis is a noninvasive tool to assess cardiac autonomic function. The value of HRV is that it can detect CAN before conventional tests of cardiovascular autonomic function like the Ewing battery [46].

In the Framingham Heart Study, both frequency and time domain measures of HRV were found to be inversely associated with the risk of mortality [7]. In the Atherosclerosis Risk In Communities (ARIC) Study, decreased HRV was independently associated with the risk of developing coronary heart disease [89].

On the other hand, T2DM is associated with accelerated atherosclerosis, with markedly increased incidence of cardiovascular morbidity and mortality [10].

Thus, early detection of atherosclerosis is of utmost importance in T2DM to prevent negative outcomes.

Framingham Risk Score has been proved useful for detection of coronary heart disease risk before its serious negative end points become apparent [1112]. Notwithstanding, due to limitations of this scoring system surrogate markers of atherosclerosis have been devised to enhance prevention and earlier diagnosis of coronary heart disease in T2DM [1314].

We performed this study to evaluate whether CAN as measured by decreased HRV is associated with increased risk of subclinical atherosclerosis in T2DM.

2. Materials and Methods

2.1. Subjects

This case-control study was performed in Dr. Shariati hospital, Tehran University of Medical Sciences. A total of 57 diabetic and 54 nondiabetic control subjects were recruited in this study. Participants were drawn from the list of diabetics who attended diabetes outpatient clinics in Dr. Shariati Hospital, Tehran, Iran, for regular followup between September 2010 and January 2011. The control group was healthy relatives in law of diabetic participants. The study protocol was approved by the ethics committee of Tehran University of Medical Sciences, and the participants signed their informed consent at the time of recruitment.

The inclusion criteria were defined as both sexes, aged between 30 and 65 years. Current or previous smokers, subjects with diabetic foot, renal failure (GFR < 90), history of malignancy, and cirrhosis were excluded from the study. In addition, none of the participants had clinical coronary heart disease as evidenced by Rose questionnaire and electrocardiographic (ECG) criteria (Minnesota codes 1.1–1.3, 4.1–4.4, 5.1–5.3, and 7.1) at the time of the study.

Patients with proliferative retinopathy were excluded from the study according to their results of retinoscopy which was performed by two ophthalmologists. Peripheral neuropathy was diagnosed using the10-gram Semmes-Weinstein monofilament test on the plantar foot surface in diabetic patients. Failure to sense the filament was considered as diabetic neuropathy and resulted in exclusion from the study.

Height was measured with a Stadiometer, and weight was assessed by a calibrated beam balance. Body mass index (BMI) was calculated as weight (Kg) divided by height (M) squared. Blood pressure was measured twice (5 minutes apart) using a standard calibrated mercury sphygmomanometer on both right and left arms after the participants had been sitting calm for at least 10 minutes. The highest blood pressure of two sides was considered as participant's blood pressure. The two groups were matched based on age.

2.1.1. Definitions

Diabetes mellitus was defined as patients with FBS ≥ 126 mg/dL, or 2-h postload glucose ≥200 mg/dL or else were using oral hypoglycemic agents [14]. Hypertensive patients were those with systolic blood pressure of ≥ than 140 or diastolic blood pressure of ≥90 mmHg or were using antihypertensive drugs [15].

2.2. Laboratory Data

Venous blood samples were collected in the morning after 12 h fasting. The blood samples were centrifuged, and then serum was collected for measuring the biomedical parameters.

In all the participants, fasting plasma glucose (FBS) and 2-h postload glucose levels were measured.

Plasma levels of glucose, triglyceride (TG), total cholesterol, HDL cholesterol, LDL cholesterol, creatinine, blood urea nitrogen (BUN), and highly sensitive C-reactive Protein (hs-CRP) were measured by a colorimetric method using Pars Azmoon kit with an autoanalyzer (Hitachi 902, Boehringer Mannheim Germany). Serum Insulin concentration was assessed by immunoassay (ELISA) using a Bioscience kit (Monobind kit, USA). HbA1c was detected by High-performance liquid chromatography (HPLC) (Knauer, Germany), coupled with fluorescence detector. The method was validated over a linearity range of 1–100 μmol/L of the plasma. The intra- and interassay coefficients of variation (CVs) for all these measurements were <4%, which was less than allowed CVs. A morning clean catch midstream urine sample was collected for measuring creatinine and evaluation of microalbuminuria.

Homeostasis model assessment (HOMA) index was calculated as the product of the fasting plasma insulin level (μIU/mL) and the fasting plasma glucose level (mmol/L), divided by 22.5.

2.2.1. Surrogate Atherosclerosis Markers

We measured the following markers of subclinical atherosclerosis (SCA) in our participants.

Carotid Intima Media Thickness (CIMT) —

Ultrasonographic analysis of the carotid artery was performed with a high-resolution ultrasound scanner, equipped with a linear array 13 MHz transducer (MyLab 70 XVision, Biosound Esaote, USA). One physician who was blind to the nature of the group performed CIMT measurements. A rapid cross sectional scanning was made in the first step to pinpoint the possible plaques. The scan was started from the proximal part of the common carotid artery (CCA) toward the bifurcation, followed by scanning the internal and then the external carotid arteries. This process was followed by a longitudinal scanning of the CCA. In this step, the dynamic sequence images were stored for the following measurements of CIMT. A segment of the artery (usually where the vessel walls were most clearly seen throughout the recording) was magnified to identify a distinct lumen-intima and media-adventitia interface. CIMT was defined as the distance between the leading edge of the lumen-intima interface and the leading edge of the media-adventitia interface. For detection of CIMT, a special software (Vascular tools 5 (Medical Imaging Applications LLC, USA)) was employed. The regions of interest were defined as 1.0 cm distal to the bifurcation, the bifurcation and 1.0 cm proximal to the internal carotid artery in both near and far walls. Then for each subject CIMT was reported as the average of 12 measurements (6 measurements from the right and 6 from the left carotid artery).

Coronary Artery Calcium Score (CAC) —

Anterior-posterior and lateral chest scout views were first obtained for planning. Calcium score images were obtained with a Phillips 64 MDCT scanner using 64 × 2.5 mm × 400 ms with 120 KVP and 50–75 mAs to cover the entire heart and proximal ascending aorta. A positive calcium score was defined by 130 HU with an area of 1 mm2 or greater. The amount of calcium was quantified using the Agatston scoring method [16].

Flow-Mediated Dilation (FMD) —

FMD of the brachial artery was measured according to the American College of Cardiology guidelines [17]. The diameter of the right brachial artery was measured 3–5 cm above the antecubital fossa. Then a blood pressure cuff was inflated around the right forearm to at least 50 mmHg above the systemic blood pressure for 4-5 minutes. 60 seconds after cuff release, the diameter of the brachial artery was measured again. The brachial FMD was calculated as the percentage of change in the maximum postocclusion diameter of the brachial artery relative to the mean baseline diameter. All the measurements were performed in the end-diastolic phase coinciding with the R-wave on an electrocardiograph monitor. Every measurement was taken as the average of 3 consecutive cardiac cycles. FMD values greater than 5–10% were considered normal [17].

Heart Rate Variability —

The evaluation of HRV was performed in a quiet and temperature-controlled room according to the guidelines of the Task Force for Pacing and Electrophysiology [18]. Participants were advised to abstain from caffeinated food and beverages on the day of their assessments. Repeat assessments were performed at precisely the same time of day after 48 hours. After 15 minutes of supine rest with a regular and calm breathing pattern, a continuous 10-minute ECG recording was collected using an applanation tonometer interface with HRV software (SphygmoCor, AtCor Medical Pty, Sydney, Australia). The high-frequency (HF band: 0.15–0.45 Hz), low-frequency (LF band: 0.04–0.15 Hz), and very-low-frequency (VLF band: 0.01–0.04 Hz) components of HRV (measured in absolute units; i.e., ms2) were obtained. Total power (TP) of HRV was also calculated to be used in regression analysis as a global marker of cardiac autonomic function. Normalized HF and LF powers were determined by dividing their absolute powers by the total power minus the VLF component and multiplied by 100 [1820]. From the electrocardiographic recording, the following statistical and geometric time domain indices were calculated from RR intervals: standard deviation of the NN intervals (SDNN), the square root of the mean squared difference of successive NNs (RMSSD), and the triangular index (TI). Frequency domain variables including total, HF, and LF powers and LF : HF ratio were derived from spectral analysis of successive R-R intervals [18].

Assessment of Cardiac Autonomic Function —

HRV measurement was performed after Valsalva and standing maneuvers in addition to supine state, using SphygmoCor software (SphygmoCor, AtCor Medical Pty, Sydney, Australia).

For valsalva maneuver, the participant was requested to blow into the mouthpiece of the device manometer to a pressure of 40 mmHg for 15 seconds. Then the valsalva ratio was calculated as the relationship between the longest and shortest R-R intervals after strain. For standing maneuver, the participant was requested to breathe at a normal pace for 5 minutes in the supine state. Then he/she was asked to go from supine to a full upright position and remain standing until the end of measurement. The standing ratio was calculated as longest R-R interval around the 30th beat after standing up to the shortest R-R interval around the 15th beat during standing.

We also performed deep breathing test by calculating the ratio of maximum and minimum heart rates during six cycles of paced deep breathing (E/I index) [21].

2.3. Data Analysis

For data analysis, the SPSS (version 18.0) was used. Normality of data distribution was evaluated by the Kolmogorov-Smirnov test. For data not normally distributed, the Mann-Whitney U test was applied. TP, LFnorm, HFnorm, LF : HF, RMSSD, and valsalva ratio were log-transformed before analysis due to their nonnormal distribution. For comparing data with normal distribution, unpaired t-test was used. Adjustment for confounding factors was performed using univariate analysis of variance (ANOVA). Correlation of variables was demonstrated using Pearson's and Spearman's correlation coefficients in normal distributed parametric and nonparametric variables, respectively. For assessment of association of variables, linear regression and logistic regression were used for parametric and binary variables, respectively.

3. Results

Table 1 summarizes the general characteristics and subclinical atherosclerosis markers of the two groups. Mean duration of diabetes was 8.6 years in T2DM participants. Systolic blood pressure was significantly higher and HDL-C levels were significantly lower in diabetics. Total- and LDL-cholesterols were significantly higher in diabetics. Fasting insulin and). HbA1c levels were significantly higher in diabetics than in controls. CIMT and CAC scores were significantly higher, while brachial FMD was significantly lower in diabetics.

Table 1
General characteristics of participants.

Table 2 compares the autonomic and HRV indices between T2DM and control groups. SDNN and RMSSD were significantly lower in diabetics than in controls. Significant reduction of spectral power in HF band (expressed as normalized units) and in total power was also observed in our T2DM participants relative to controls.

Table 2
Heart rate variability and autonomic function indices.

Valsalva ratio, E/I index and heart rate response to standing were significantly lower in diabetics relative to controls.

HF power was highly correlated to total power. In addition, the observed associations for total power were similar to those of HF power. So we performed our analyses with total power for convenience.

Unadjusted correlations between total power and conventional CHD risk factors revealed that diastolic BP in all participants and BMI in diabetics were negatively associated with total power (Table 3).

Table 3
Partial correlation of total power and coronary risk factors after adjustment for diabetes mellitus.

Multiple logistic regression of the association between surrogate atherosclerosis markers and total power spectra revealed that CIMT was inversely and independently associated with total power both in diabetics and controls (Table 4). This relationship between total power and CIMT showed a dose-response pattern throughout the distribution of HRV. On the other hand, although CAC score also was inversely associated with HRV in a stepwise manner, this relation lost its significance after adjustment for diabetes (Table 2). The relationship between FMD% and total power was lost after multiple regression (Table 4).

Table 4
Association between categorized CIMT and quartiles of total power in multivariate logistic regression model.

Figure 1 shows the median values of the total power in normal participants (controls) and diabetics divided by tertiles according to HbA1c levels. We found an inverse association between total power and median HbA1c levels.

Figure 1
Median of total power in different HbA1c levels.

4. Discussion

We found that substantial autonomic dysfunction was present in our early T2DM patients even before overt clinical symptoms of CVD became apparent. It is noteworthy that involvement of the vagal parasympathetic component of autonomic nervous system was obvious in our T2DM patients. This is evidenced by increased resting heart rate and decreased Valsalva ratio; E/I index and standing ratio in diabetics relative to controls. These findings are in line with those of Freccero et al. who reported a high frequency of parasympathetic and sympathetic neuropathy in both type 1 and type 2 diabetic patients [22]. They suggested that severe damage to large myelinated nerve fibers in addition to the widespread neurological degeneration which usually affects the small nerve fibers of the autonomic nervous system was responsible for profound parasympathetic neuropathy in patients with T2DM. Other researchers also found appreciable degree of autonomic neuropathy in patients with T2DM [2324].

In fact significantly reduced HRV measures in T2DM patients compared to controls have been previously verified in large-population-based studies [2527]. In the Hoorn Town of The Netherlands HF, and LF powers and SDNN were lower among T2DM participants compared to those with normal fasting glucose [25]. The same results had also been documented in the Framingham Heart Study and in the Atherosclerosis Risk in Communities (ARIC) cohort [2628].

The significance of our findings is that HRV reduction in diabetics was present since the early stages of diabetes even before clinical atherosclerotic cardiovascular disease became evident. Thus, it is imperative to screen for autonomic neuropathy as early as possible in T2DM to prevent or retard its serious consequences.

In addition, we found that surrogate atherosclerosis markers were associated with lower HRV. Especially, increased CIMT in our T2DM participants was significantly associated with decreased HRV. This association was independent of conventional risk factors such as hypertension, BMI, and dyslipidemia. Also, this association was of greater magnitude in diabetic than nondiabetic participants. A stepwise increase in the odds of CIMT with decreasing quartile of total power was observed in those with T2DM.

Gottsäter et al. in a longitudinal study of T2DM patients found a similar correlation between decreasing HRV in the form of total power and increasing CIMT [28]. In their study, this relation was observed both at baseline and with progression of diabetes during 3 years of followup. The association between decreased total power and E/I ratio with increased CIMT has also been observed by Eller et al. previously [29]. In addition, our findings are concordant with those of researchers in the ARIC cohort who had previously reported significant association between lower HRV and coronary heart disease in diabetic subjects [30].

Furthermore, increased CAC score was also associated with lower HRV in our T2DM participants; however, after adjustment for diabetes and other conventional risk factors this relationship lost its significance. Notwithstanding, Rodrigues et al. in their recent study of type 1 diabetes patients found that reduced HRV prospectively predicted progression of coronary artery calcium as a powerful cardiovascular disease risk marker [31]. Previously Colhoun et al. had reported clustering of HRV with coronary calcification and other cardiovascular risk factors in asymptomatic young type 1 diabetes patients [32].

We did not find an independent association between reduced HRV and endothelial dysfunction in this study after adjusting for conventional risk factors. However, Pinter et al. in a recent study of young healthy male volunteers found a significant positive correlation between vagal HRV indices (RMSSD, PNN50, and HF power) and normalized flow-mediated dilation [33]. They suggested that endothelial mediators especially nitric oxide released locally from the capillary endothelium could enhance the effects of vagal inputs during respiratory cycle. Vagal discharge increases during expiration and decreases during inspiration, producing respiratory sinus arrhythmia. As a result the major component of short-term HRV which is respiratory related is influenced by endothelial dysfunction.

The association of decreased HRV with atherosclerosis markers could be due to ischemic damage to cardiac nerves [34], which may have been occurred before these markers became apparent. In line with this hypothesis, Gautier et al. in their study of participants in the Pittsburg Study and Kuopio Ischemic Heart Disease Risk Factor Trial found a significant negative relation between mean CIMT and LF power. In other words, LF power, which reflects sympathovagal balance and baroreceptor buffering, was correlated with CIMT. They suggested that decreased LF power could be attributed to chronic downregulation of vascular sympathetic receptors over time. This may potentially cause vascular smooth muscle cell differentiation with subsequent intimal migration and extracellular matrix production [35]. Gottsäter et al. also concluded based on their findings that decreased LF power could predict the progression of atherosclerosis in T2DM [28]. These changes are characteristic of atherosclerotic progression. In our study although LF power was lower in diabetics than controls, this difference hardly became significant (P < 0.10). The current study cannot establish this array of events in the course of atherosclerosis development. Further experimental prospective investigations are needed to resolve this cause-and-effect relationship.

Advanced glycation end products may play a critical role in damage to cardiac nerves and subsequent autonomic dysfunction, which promotes progression of atherosclerosis. The inverse association between total power and median HbA1c levels in our study is concordant with this hypothesis. Colhoun and colleagues found that in young type 1 diabetic patients HbA1c was a very good proxy marker of diabetes which could explain differences in HRV indices between diabetics and nondiabetics [32]. On the other hand, Mäkimattila et al. found that total power was the factor most influenced by chronic hyperglycemia in type 1 diabetes patients. In addition, they showed that total power and retinopathy score were the most sensitive measures of diabetes complications [36]. In conclusion, we found that autonomic dysfunction, especially parasympathetic neuropathy, was present since early stages in T2DM. This was strongly related to subclinical atherosclerosis markers in these patients. Specifically decreased total power as a global measure of parasympathic neuropathy was independently associated with increased CIMT.

Limitations —

A limitation of this study is its cross-sectional nature. So it is not possible to establish a definite cause-and-effect relationship between findings as one is not able to differentiate whether decreased HRV precedes atherosclerosis markers or appears subsequently. In addition, the sample size was relatively limited, and we reported P values < 0.10.


Articles from ISRN Endocrinology are provided here courtesy of Hindawi Publishing Corporation
 
 
Also, the following excellent article is reproduced from the Journal of Diabetes & Metabolic Disorders at https://jdmdonline.biomedcentral.com/articles/10.1186/2251-6581-12-55:
 

Association of cardiac autonomic neuropathy with arterial stiffness in type 2 diabetes mellitus patients

  • Ataollah Bagherzadeh,
  • Afshin Nejati-Afkham,
  • Yaser Tajallizade-Khoob,
  • Akbar Shafiee,
  • Farshad Sharifi,
  • Morteza Abdar Esfahani,
  • Zohre Badamchizade,
  • Sudabeh Alatab and
  • Hossein FakhrzadehThis email address is being protected from spambots. You need JavaScript enabled to view it.
Journal of Diabetes & Metabolic Disorders201312:55

DOI: 10.1186/2251-6581-12-55

Received: 31 July 2013

Accepted: 30 September 2013

Published: 20 December 2013

Abstract

Background

Diabetic patients are at the risk of cardiac autonomic neuropathy (CAN) and arterial stiffness. This study aimed to investigate the association of heart rate variability (HRV) as an index for CAN and pulse wave velocity (PWV) as an index for arterial stiffness.

Methods

Uncomplicated diabetes type-2 patients who had no apparent history of cardiovascular condition underwent HRV and PWV measurements and the results were compared with the control group consisting of non-diabetic peers. Also, the findings were adjusted for the cardiovascular risk factors and other confounding factors.

Results

A total of 64 diabetic patients (age= 52.08±8.50 years; males=33 [51.6%]) were compared with 57 controls (age= 48.74±6.18 years; males=25 [43.9%]) in this study. Hypertension, dyslipidemia, and thereby systolic blood pressure and statin use were significantly more frequent in the diabetic group, while the serum levels of cholesterol, HDL-C and LDL-C were significantly higher in the controls. Pulse wave was significantly increased in the diabetic patients (p<0.001). Main HRV parameters were significantly lower in diabetics than in controls. After adjustment for the confounders, PWV and HRV remained significantly different between the groups (p=0.01 and p=0.004, respectively). Multiple logistic regression of the association between pulse wave velocity and HRV index was independently significant both in diabetics and controls.

Conclusions

There exists a significant relationship between heart rate variability and arterial stiffness as a measure for atherosclerosis in diabetic patients, although the role of the confounding factors is noteworthy.

Introduction

More than half of the mortality in diabetic patients occurs due to cardiovascular disease [1]. Although most of this risk stems from atherosclerosis along with vascular ageing, there are other conditions involved [2]. Cardiac autonomic neuropathy (CAN) is a serious complication of diabetes mellitus, shown to influence both mortality and cardiovascular events in these patients [3]. As the heart rate and vascular tone are regulated via the autonomic system, CAN can increase heart rate variability and decrease myocardial perfusion [4].

On the other hand, heart rate variability (HRV) can be assessed easily to measure CAN, much earlier than its clinical appearance [5]. It has been shown that low HRV is associated with increased mortality in patients with ischemic heart disease or diabetes mellitus [36]. HRV is also a sensitive indicator of baroreflex control, specifically the vagal control [78]. Therefore, arterial stiffness may affect baroreceptor function and thereby, HRV. Increased arterial stiffness evaluated by pulse wave velocity (PWV) and/or augmentation index has been associated with the presence of coronary atherosclerosis and worse cardiovascular prognosis both in general population [910] and specific disease groups, including diabetes mellitus [11]. Therefore, understanding the exact relationship of heart rate variability, as an index for CAN, with arterial stiffness is crucial.

The aims of the present study were to investigate (i) the association of disturbed PWV, as an index for increased arterial stiffness, and HRV, as an index for CAN, in the presence or absence of uncomplicated diabetes mellitus and (ii) the relation of PWV with HRV in uncomplicated diabetic patients.

Methods

In this case–control study, uncomplicated diabetic type 2 (T2DM) patients who were referred to the Diabetes clinic of Dr. Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran, between August 2011 and December 2012 were recruited. The control group consisted of their spouse or relatives who were proved to be non-diabetic. The inclusion criteria were defined as both sexes, aged between 30 and 65 years. Individuals with clinically proven coronary heart disease, diabetic foot, diabetic retinopathy or nephropathy, renal failure (GFR < 90), history of malignancy, and cirrhosis were excluded from the study. Height was measured with a Stadiometer, and weight was assessed by a calibrated beam balance. Body mass index (BMI) was calculated as weight (Kg) divided by height (M) squared. Blood pressure was measured twice (5 minutes apart) using a standard calibrated mercury sphygmomanometer on both right and left arms after the participants had been sitting calm for at least 10 minutes. The highest blood pressure of two sides was considered as participant’s blood pressure.

All the participants signed an informed consent at the time of recruitment and the study protocol was approved by the ethics committee of Tehran University of Medical Sciences, and the board of research at Dr. Sahriati hospoital.

Diabetes mellitus was defined as patients with fasting blood sugar (FBS) ≥ 126 mg/dL, or 2-h postprandial glucose ≥200 mg/dL or those who were using insulin or oral hypoglycemic agents. Hypertensive patients were those with systolic blood pressure of ≥than 140 or diastolic blood pressure of ≥90 mmHg or were using antihypertensive drugs.

Venous blood samples were drawn from the anticubital vein in the morning after 12 h fasting. The blood samples were centrifuged, and then serum was collected for measuring the biochemical parameters.

In all the participants, FBS and 2-h postprandial glucose levels were measured. Plasma levels of glucose, triglyceride (TG), total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), creatinine, and blood urea nitrogen (BUN) were measured by a colorimetric method using Pars Azmoon® kit with an autoanalyzer (Hitachi 902, Boehringer Mannheim Germany). HbA 1 C was detected by High-performance liquid chromatography (HPLC) (Knauer, Germany), coupled with fluorescence detector. The method was validated over a linearity range of 1–100 μmol/L of the plasma. The intra- and interassay coefficients of variation (CVs) for all of the measurements were <4%, which was less than allowed CVs.

Evaluation of HRV was performed in a quiet and temperature-controlled room according to the guidelines of the Task Force for Pacing and Electrophysiology [5]. Participants were advised to abstain from caffeinated food and beverages on the day of assessment. Repeat assessments were performed at precisely the same time of day after 48 hours. After 15 minutes of supine rest with a regular and calm breathing pattern, a continuous 10-minute ECG recording was collected using an applanation tonometer interface with HRV software (SphygmoCor, AtCor Medical Pty, Sydney, Australia). The high-frequency (HF band: 0.15–0.45 Hz), low-frequency (LF band: 0.04– 0.15 Hz), and very-low-frequency (VLF band: 0.01–0.04 Hz) components of HRV (measured in absolute units; i.e., ms 2 ) were obtained. Total power (TP) of HRV was also calculated to be used in regression analysis as a global marker of cardiac autonomic function.

Normalized HF and LF powers were determined by dividing their absolute powers by the total power minus the VLF component and multiplied by 100 [512].

From the electrocardiographic recording, the following statistical and geometric time domain indices were calculated from RR intervals: standard deviation of the NN intervals (SDNN), and the square root of the mean squared difference of successive NNs (RMSSD). Frequency domain variables including total, HF, and LF powers and LF:HF ratio were derived from spectral analysis of successive R-R intervals [5].

HRV measurement was performed after Valsalva and standing maneuvers in addition to supine state, using SphygmoCor software (SphygmoCor, AtCor Medical Pty, Sydney, Australia). For Valsalva maneuver, the participant was requested to blow into the mouthpiece of the device manometer to a pressure of 40 mmHg for 15 seconds. Then the Valsalva ratio was calculated as the relationship between the longest and shortest R-R intervals after strain. For the standing maneuver, the participant was requested to breathe at a normal pace for 5 minutes in the supine state. Then, the participant was asked to change position from supine to a full upright and remain erected until the end of the test. The standing ratio was calculated as longest R-R interval around the 30th beat after standing up to the shortest R-R interval around the 15th beat during standing.

PWV was measured using the SphygmoCor System (AtCor Medical Pty Ltd Head Office, West Ryde, Australia), with the individual in the supine position. The pulse waves of the carotid and femoral arteries were analyzed, estimating the delay according to the ECG wave and calculating PWV. PWV was calculated as the ratio of the distance travelled (calculated as distance in mm of distal minus proximal, where measurements are performed from the supra-sternal notch to the sampling site) and the foot-to-foot time delay between the pulse waves and expressed in meters per second (m/sec).

Statistical analysis

Continuous data are presented as mean ± SD. For comparing data with normal distribution, unpaired t-test was used. Correlation of variables was demonstrated using Pearson’s and Spearman’s correlation coefficients in normal distributed parametric and nonparametric variables, respectively. For assessment of the association of variables, linear regression and logistic regression were used for parametric and binary variables, respectively. P-values were always 2-sided, and P < 0.05 was considered significant. The SPSS statistical software package (version 18.0 for Windows; SPSS Inc. Chicago, IL) was used for data analysis.

Results

A total of 64 diabetic patients (age= 52.08±8.50 years; males=33 [51.6%]) were compared with 57 controls (age= 48.74±6.18 years; males=25 [43.9%]) in this study. Table 1 depicts the general characteristics and clinical parameters of both groups. Rate of hypertension, dyslipidemia, and thereby systolic blood pressure and statin use were significantly higher in the diabetic group, while the serum levels of cholesterol, HDL-C and LDL-C were significantly higher in the control group.
Table 1

General characteristics of the study population

Characteristics

Normal (N=57)

Diabetic (N=64)

P-value

Age (years)

48.74 ± 6.18

52.08 ± 8.50

0.15

Sex (male) %

25 (43.9)

33 (51.6)

0.39

BMI (kg/m2)

29.12 ± 5.06

27.93 ± 4.46

0.12

Hypertension

4 (7.0)

23 (35.9)

<0.001

Dyslipidemia

9 (15.8)

36 (57.1)

<0.001

Smoking, n (%)

1 (1.8)

8 (12.5)

0.02

Statin use

2 (3.5)

27 (42.9)

<0.001

FBS (mg/dl)

93.84 ± 13.22

162.60 ± 56.32

<0.001

Hb A1c (%)

5.31 ± 0.68

7.95 ± 1.70

<0.001

Cholesterol (mg) (mg/dl)

201.80 ± 31.04

174.12 ± 38.50

<0.001

Triglyceride (mg/dl) (mg/dl)

173.52 ± 99.17

194.08 ± 120.45

0.42

HDL-C (mg/dl)

46.25 ± 10.74

40.34 ± 8.23

0.001

LDL-C (mg/dl)

114.52 ± 22.43

95.12 ± 23.13

<0.001

Creatinine (mg/dl)

0.95 ± 0.13

0.94 ± 0.15

0.62

BUN

12.88 ± 3.19

12.36 ± 4.15

0.45

Hemoglobulin

14.87 ± 4.37

14.30 ± 1.44

0.34

SBP (mmHg)

123.46 ± 14.09

131.00 ± 17.33

0.01

DBP (mmHg)

77.47 ± 10.11

76.03 ± 8.73

0.4

BMI: Body mass index; BUN: Blood urea nitrogen; DBP: Diastolic blood pressure; FBS: Fasting blood sugar; HDL: High density lipoprotein; hs-CRP: High sensitive C-reactive protein; IFG: Impaired Fasting Glucose; LDL: Low density lipoprotein; SBP: Systolic blood pressure.

Table 2 compares the PWV and HRV indices between the study groups. Pulse wave velocity was significantly increased in the diabetic patients (p<0.001). RMSSD and HRV index were significantly lower in diabetics than in controls (p=0.02 and p<0.001, respectively). Significant reduction of total power was also observed in the diabetic patients relative to controls.
Table 2

Comparing pulse wave velocity and heart rate variability indices between the study groups

Variables

Normal (N=57)

Diabetic (N=64)

P-value

Pulse wave velocity (m/s)

8.00 ± 1.61

10.11 ± 2.45

<0.001

RMSSD (ms)

31.78 ± 21.27

20.13 ± 19.51

0.02

HRV index

7.78 ± 2.94

5.57 ± 2.22

<0.001

Heart rate(bpm)

68.95 ± 9.44

73.64 ± 8.41

0.005

PNN 50

9.58 ± 14.56

3.01 ± 7.10

0.002

LF norm (ms2)

55.98 ± 18.79

61.65 ± 20.99

0.12

HF norm (ms2)

44.02 ± 18.78

38.34 ± 20.99

0.12

LF:HF ratio

1.83 ± 1.70

2.72 ± 2.73

0.03

Total power (ms2)

1133.17 ± 1266.26

703.73 ± 1279.76

0.06

Valsalva ratio

1.58 ± 0.28

1.44 ± 0.31

0.01

Standing ratio

1.27 ± 0.13

1.23 ± 0.20

0.29

HF: High frequency; HRV: Heart rate variability; LF: low frequency; RMSSD: the square root of the mean squared difference.

After adjustment for the confounding variables, including age, BMI, hypertension, dyslipidemia, smoking, statin use, FBS, total cholesterol and systolic blood pressure, PWV and HRV remained significantly different between the groups (p=0.01 and p=0.004, respectively).

As HF power was highly correlated with the total power and their observed associations were similar, we performed our analyses using total power. Unadjusted correlations between total power and cardiovascular parameters showed that the PWV was positively correlated with the total power in diabetic patients while the correlation was reverse in non-diabetic controls and total population. Also, hypertension and triglyceride levels were positively correlated with the total power in the diabetic patients (Table 3).
Table 3

Partial and total correlations of the total power with PWV and other cardiovascular parameters

Characteristics

Nondiabetic subjects

Diabetic subjects

All subjects

Age (years)

−0.42 †

−0.16

−0.14

Sex (male) %

0.17

0.06

−0.07

BMI (kg/m2)

0.07

−0.23

−0.06

Hypertension

0.2

0.28 *

0.15

Dyslipidemia

0.14

0.19

0.2 *

Current smoker (%)

0.02

−0.17

−0.17

Statin use

−0.11

−0.14

−0.12

FBS (mg/dl)

−0.23

−0.003

−0.02

Hb A1c (%)

0.004

−0.09

0.09

Cholesterol (mg) (mg/dl)

−0.04

0.04

−0.03

Triglyceride (mg/dl) (mg/dl)

−0.02

0.25 *

−0.08

HDL-C (mg/dl)

−0.13

−0.02

−0.10

LDL-C (mg/dl)

−0.04

−0.10

−0.001

Creatinine (mg/dl)

−0.10

0.18

0.06

BUN

−0.06

−0.05

−0.12

Hemoglobulin

−0.20

0.21

0.02

SBP (mmHg)

−0.10

−0.31 *

−0.12

DBP (mmHg)

−0.35 †

−0.36 †

−0.32 †

Pulse wave velocity (m/s)

−0.28 *

0.37 †

−0.19 *

* p<0.05.

† p<0.01.

BMI: Body mass index; BUN: Blood urea nitrogen; DBP: Diastolic blood pressure; FBS: Fasting blood sugar; HDL: High density lipoprotein; hs-CRP: High sensitive C-reactive protein; IFG: Impaired Fasting Glucose; LDL: Low density lipoprotein; SBP: Systolic blood pressure.

Multiple logistic regression showed that pulse wave velocity was independently associated with HRV index both in diabetics and controls (Table 4). This relationship showed a dose–response pattern throughout the distribution of HRV. On the other hand, this relation lost its significance after adjustment for diabetes and particularly in the multiple regression model, including age, hypertension, dyslipidemia, smoking, BMI, and systolic blood pressure.
Table 4

Association between pulse wave velocity and quartiles of HRV index in multivariate logistic regression model

 

Unadjusted OR (CI)

Diabetes adjusted OR (CI)

Full adjusted OR (CI)

Fist quartile of HRV index†

     

Second quartile of total power

0.73 (0.57, 0.92)

0.81 (0.63, 1.04)

0.93 (0.81, 1.06)

Third quartile of total power

0.51 (0.38, 0.71)

0.57 (0.41, 0.80)

0.55 (0.37, 0.84)

Fourth quartile of total power

0.55 (0.40, 0.74)

0.64 (0.47, 0.89)

0.91 (0.61, 1.37)

P trends

<0.001

0.001

0.01

† First quartile of the HRV was considered as the reference.

CI: confidence interval; HRV: Heart rate variability; OR: Odd’s ratio; PWV: Pulse wave velocity.

Discussion

In this study, we observed that considerable cardiac autonomic dysfunction exists in the uncomplicated diabetic patients in comparison with the normal controls, as well as an increase in the arterial stiffness, measured by pulse wave velocity.

Current evidence confirms that HRV is a good measure of cardiac autonomic neuropathy in diabetic patients and its decrease is accompanied by increased mortality and morbidity [13]. In our study, increased resting heart rate and decreased Valsalva ratio and standing ratio in the diabetic patients illustrate the parasympathetic involvement of the autonomous system as compared with the normal controls. This has also been shown previously both in type 1 and type 2 diabetes patients [1415].

Decreased HRV in the uncomplicated diabetes patients of our study and previous studies highlights the obscure process of autonomic neuropathy in diabetic patients that begins even before clinical atherosclerotic cardiovascular disease becomes apparent [16].

It has also been shown that surrogate atherosclerosis markers were associated with lower HRV, and increased carotid intima media thickness (CIMT) in T2DM participants was significantly associated with decreased HRV, independent from conventional cardiovascular risk factors [16]. Therefore, the presence of cardiac autonomic neuropathy should be considered much earlier in the course of diabetes, rather than after the development of clinical cardiovascular disease.

PWV is known as a potentially applicable atherosclerotic risk marker irrespective of classical cardiovascular risk factors and ethnicity [17]. In previous studies, arterial stiffness assessed by pulse wave analysis had a prognostic value for cardiovascular morbidity and mortality, mostly in hypertensive patients [181920]. One study demonstrated that increased aortic pulse wave velocity was associated with the presence of angiographic coronary artery disease in overweight and obese patients, although the arterial stiffness indices were not consistently associated with obesity [21]. Similarly, it has been shown that cardiac parasympathetic function is a strong predictor of large arterial stiffness, in young type 1 diabetes patients without macrovascular and renal complications [22]. In the Pittsburgh Epidemiology of Diabetes Complications study, cardiac autonomic neuropathy was associated with increased arterial stiffness indices, in patients with childhood-diagnosed type 1 diabetes [23]. Moreover, a novel relationship between arterial stiffness, hyperinsulinaemia and autonomic neuropathy in a Type 2 diabetic population has been shown in a study which signifies their pathogenic roles in the development of cardiovascular disease in diabetic patients [13].

Based on our findings and previous works, one could suggest that atherosclerosis, both as a result of diabetes and increased age is influenced by the cardiac autonomic neuropathy, which in turn results in increased risk of cardiovascular diseases and related mortality in the type 2 diabetes patients.

Study limitations

Among limitation to the study, we can mention that our measurements were cross-sectional and we could not assess how the changes in both HRV and PWV through time, as well as the fluctuations in the serum glucose levels and glycosated hemoglobin, affect each other. We also did not perform glucose tolerance test in the normal controls, so there is a probability that those with glucose intolerance may have some degrees of disturbed HRV and PWV. Also the effects of the type of diabetes treatment and other prescribed medications on HRV and PWV need to be investigated in future studies.

Conclusion

In this study, we observed increased arterial stiffness and decreased heart rate variability in the uncomplicated type 2 diabetes patients as compared with normal controls. The relationship between heart rate variability indices and pulse wave velocity was significant after adjustment for diabetes; however, this effect was lost after adjustment for confounders. Based on the findings of this study, it seems that there exists a relationship between heart rate variability and arterial stiffness as a measure for atherosclerosis in diabetic patients, although the role of the confounding factors should be taken into account.

Copyright

© Bagherzadeh et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

----------------------------------------------------------------------------------------------------------------------------------------------------------

 

Heart Rate Variability (HRV) is the measure of the variability between heartbeats and the health of the autonomic nervous system. Imbalances between the parasympathetic nervous system (maintains balance body functions) and sympathetic nervous system ( which controls emergency energy in stressful situations) is an indicator of health issues such as heart arrhythmia or diabetes.

Also denoted as the RR interval, an ECG can measure the patient’s HRV against the patient’s resting heart rate. Low HRV rates are a key indicators of heart disease, stress and the chance of heart attack survivability. Using this data, a doctor can diagnose existing issues and proscribe a treatment in response.

Sources and Research:
Heart Rate Variability: Standards of Measurement, Physiological Interpretation, and Clinical Use

--------------------------------------------------------------------------------------------------------------------------------

*** SPECIAL NOTE FROM DR. WICHMAN ***

For additional information regarding Pulse Wave Analysis (PWA), please read: (1) http://atcormedical.com/wp-content/uploads/2016/06/Advancements-in-Hypertension-Management-White-Paper-03.2016-2.pdfand (2) http://atcormedical.com/wp-content/uploads/2016/06/Central-Arterial-Pressure-in-Hypertension-Management.pdf.

----------------------------------------------------------------------------------------------------------------------------------------------------------

 

Blood Pressure and Pulse Wave Analysis (PWA)

Cardiovascular Health Assessment

Simple, painless assessment of arterial stiffness and cardiovascular status

Why do I need this test?

Heart disease affects more people than any other disease or illness, and can develop without any symptoms. Some people may not be aware of heart disease until they have a heart attack, stroke or other health problem. A growing number of cardiovascular risk factors, including diabetes, high cholesterol, smoking, high blood pressure and age, have been linked to heart attack, stroke and heart failure. These factors often lead to stiffer arteries, which in turn increases resistance and therefore increases the work that the heart must do.

Blood pressure Pulse Wave Analysis is new technology that assists your doctor in assessing your arterial and cardiovascular health. Blood pressure measured in your arm is not the same as the blood pressure at your heart. It is your blood pressure at your heart that affects the performance of your heart, and pulse wave analysis determines your blood pressure at your heart and gives your doctor valuable information about the interaction between your heart and blood vessels. This new technique therefore complements the conventional blood pressure cuff and provides additional information on cardiac function.

What do the measurements mean?

Augmentation Index (AIx) Augmentation Index is a measure of the stiffness of your arteries. High cholesterol, smoking, diabetes, and aging can all cause the vessels that take blood from the heart (the arteries) to become stiffer. As the arteries become stiffer the heart must work harder due to the extra load on the heart.

Ejection Duration (ED) Each time our heart beats, it has a time when it is contracting and pumping blood out of the heart, and a time when it is resting and filling with blood. The ED is a measurement of how much time the heart spends pumping. When the heart spends a shorter time than normal pumping there may be problems with the ability to pump blood, while longer than normal pumping time may indicate problems with the ability for the heart to relax and fill with blood.

Subendocardial Viability Ratio (SEVR) When the heart is resting, the heart muscle is supplied with oxygen for energy. When the heart is contracting and pumping this energy is being used. The SEVR is a measure of the ability of the arterial system to meet the heart’s energy requirements. As this ratio decreases, the heart has less energy reserves available and may have a lower tolerance for physical activity.

How is a Pulse Wave Analysis assessment done?

The test is simple and painless, taking only a few minutes to perform. while you are seated in a comfortable position, the nurse or doctor will place a pencil-like sensor gently against your wrist and record a blood pressure signal from your pulse. From this recording, the Pulse Wave Analysis system will calculate the pressure waveform at the heart and provide your physician with cardiovascular measurements such as Alx, ED and SEVR.

Why are the Pulse Wave Analysis measurements important? Heart disease can be treated using a combination of diet, exercise and drug therapies. Your doctor will use this information to assist with making decisions on whether you need treatment, and if so what treatment options are best for you. It is important for your physician to see how your cardiovascular assessment changes in response to treatment.

What do I do now?

Talk to your physician about your cardiovascular risk factors, many of which may be improved by lifestyle changes and medicines. Your doctor will discuss with you how often your Pulse Wave Analysis measurements should be repeated.

Do you have any of the following risk factors?

  • High Blood Pressure
  • Diabetes or Renal Disease
  • High Blood Cholesterol
  • Overweight
  • Cigarette smoking
  • Family history of heart disease
  • Age over 40
  • Physical Inactivity

Hyperbaric Oxygen Therapy

 

Hyperbaric Oxygen Therapy (HBOT) helps all kinds of people. It’s used to help patients suffering from sports injuries, Chronic Fatigue Syndrome, infections, arthritis and a huge range of other medical conditions. As we all know, oxygen is vital for life, and life cannot exist without it. It follows that oxygen is essential for effective healing and recovery.

read more

Book Your Appointment NOW

Call (770) 232-7883

 

Click to E-Mail Us Now!

 

Our Address:

4488 N. Shallowford Road, Suite 201

Dunwoody, Georgia 30338

 

We Serve the Following Areas:

Atlanta, Georgia, Acworth, Alpharetta, Berkeley Lake, Braselton, Brookhaven, Buckhead, Buford, Canton, Chamblee, Conyers, Cumming, Dacula, Decatur, Doraville, Duluth, Dunwoody, Georgia, Flowery Branch, Gainesville, Grayson, Hoschton, Johns Creek, Kennesaw, Lawrenceville, Lilburn, Lithonia, Loganville, Marietta, Milton, Norcross, Roswell, Sandy Springs, Smyrna, Snellville, Stone Mountain, Sugar Hill, Suwanee, Tucker, Vinings, Woodstock, Georgia